4. REFERENCES
1.Radmayr, C., et al. EAU Guidelines on Paediatric Urology. In: EAU Guidelines, edition presented at the annual EAU Congress Milan 2023. ISBN 978-94-92671-19-6.
https://pubmed.ncbi.nlm.nih.gov/25477258/
2.Blok, B., et al. EAU Guidelines on Neuro-urology. In: EAU Guidelines, edition presented at the annual EAU Congress Milan 2023. ISBN 978-94-92671-19-6.
https://uroweb.org/guideline/neuro-urology/
1.Stein, R., et al. Urinary tract infections in children: EAU/ESPU guidelines. Eur Urol, 2015. 67: 546.
https://pubmed.ncbi.nlm.nih.gov/25477258
2.Blok, B., et al. EAU Guidelines on Neuro-urology. In: EAU Guidelines, edition presented at the annual EAU Congress Amsterdam 2022. ISBN 978-94-92671-16-5.
https://uroweb.org/guideline/neuro-urology/
3.Phillips B, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.
https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
4.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.
https://pubmed.ncbi.nlm.nih.gov/18467413
5.Horan, T.C., et al. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control, 2008. 36: 309.
https://pubmed.ncbi.nlm.nih.gov/18538699
6.Rubin, R.H., et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis, 1992. 15 Suppl 1: S216.
https://pubmed.ncbi.nlm.nih.gov/1477233
7.Rubin, R.H., et al. General guidelines for the evaluation of new anti-infective drugs for the treatment of urinary tract infection. The European Society of Clinical Microbiology and Infectious diseases. Taukirchen, Germany., 1993: 240.
8.U.S. Department of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research (CDER). Guidance for Industry Uncomplicated Urinary Tract Infections — Developing Antimicrobial Drugs for Treatment. 2015.
https://www.fda.gov/media/129531/download
9.U.S. Department of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research (CDER). Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry 2018.
10.Johansen, T.E., et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int J Antimicrob Agents, 2011. 38 Suppl: 64.
https://pubmed.ncbi.nlm.nih.gov/22018988
11.Singer, M., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016. 315: 801.
https://pubmed.ncbi.nlm.nih.gov/26903338
12.Bell, B.G., et al. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis, 2014. 14: 13.
https://pubmed.ncbi.nlm.nih.gov/24405683
13.WHO. Antimicrobial resistance: global report on surveillance 2014. 2014.
https://www.who.int/publications/i/item/9789241564748
14.Hulscher, M.E., et al. Antibiotic prescribing in hospitals: a social and behavioural scientific approach. Lancet Infect Dis, 2010. 10: 167.
https://pubmed.ncbi.nlm.nih.gov/20185095
15.Goff, D.A., et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. Lancet Infect Dis, 2017. 17: e56.
https://pubmed.ncbi.nlm.nih.gov/27866945
16.Dellit, T.H., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis, 2007. 44: 159.
https://pubmed.ncbi.nlm.nih.gov/17173212
17.Davey, P., et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev, 2017. 2: CD003543.
https://pubmed.ncbi.nlm.nih.gov/28178770
18.Cefai, C., et al. Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use. NICE Guidelines, 2015.
https://www.nice.org.uk/guidance/ng15
19.Schuts, E.C., et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis, 2016. 16: 847.
https://pubmed.ncbi.nlm.nih.gov/26947617
20.Hermanides, H.S., et al. Development of quality indicators for the antibiotic treatment of complicated urinary tract infections: a first step to measure and improve care. Clin Infect Dis, 2008. 46: 703.
https://pubmed.ncbi.nlm.nih.gov/18230045
21.Spoorenberg, V., et al. Appropriate antibiotic use for patients with urinary tract infections reduces length of hospital stay. Clin Infect Dis, 2014. 58: 164.
https://pubmed.ncbi.nlm.nih.gov/24158412
22.Lutay, N., et al. Bacterial control of host gene expression through RNA polymerase II. J Clin Invest, 2013. 123: 2366.
https://pubmed.ncbi.nlm.nih.gov/23728172
23.Hansson, S., et al. Untreated asymptomatic bacteriuria in girls: II--Effect of phenoxymethylpenicillin and erythromycin given for intercurrent infections. BMJ, 1989. 298: 856.
https://pubmed.ncbi.nlm.nih.gov/2497823
24.Cai, T., et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis, 2012. 55: 771.
https://pubmed.ncbi.nlm.nih.gov/22677710
25.Nicolle, L.E., et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis, 2005. 40: 643.
https://pubmed.ncbi.nlm.nih.gov/15714408
26.Kass, E.H. Asymptomatic infections of the urinary tract. Trans Assoc Am Physicians, 1956. 69: 56.
https://pubmed.ncbi.nlm.nih.gov/13380946
27.Gleckman, R., et al. Reliability of a single urine culture in establishing diagnosis of asymptomatic bacteriuria in adult males. J Clin Microbiol, 1979. 9: 596.
https://pubmed.ncbi.nlm.nih.gov/383746
28.Warren, J.W., et al. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis, 1982. 146: 719.
https://pubmed.ncbi.nlm.nih.gov/6815281
29.Kunin CM. Urinary tract infections: detection, prevention and management. 5th ed. . Baltimore: Williams and Wilkins., 1997.
30.Koves, B., et al. Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. Eur Urol, 2017. 72: 865.
https://pubmed.ncbi.nlm.nih.gov/28754533
31.Tencer, J. Asymptomatic bacteriuria--a long-term study. Scand J Urol Nephrol, 1988. 22: 31.
https://pubmed.ncbi.nlm.nih.gov/3387908
32.Asscher, A.W., et al. The clinical significance of asymptomatic bacteriuria in the nonpregnant woman. J Infect Dis, 1969. 120: 17.
https://pubmed.ncbi.nlm.nih.gov/5803281
33.Elder, H.A., et al. The natural history of asymptomatic bacteriuria during pregnancy: the effect of tetracycline on the clinical course and the outcome of pregnancy. Am J Obstet Gynecol, 1971. 111: 441.
https://pubmed.ncbi.nlm.nih.gov/4937729
34.Elder, H.A., et al. Use of sulfasymazine in the treatment of bacteriuria of pregnancy. Antimicrob Agents Chemother (Bethesda), 1966. 6: 142.
https://pubmed.ncbi.nlm.nih.gov/4862162
35.Gold, E.M., et al. Asymptomatic bacteriuria during pregnancy. Obstet Gynecol, 1966. 27: 206.
https://pubmed.ncbi.nlm.nih.gov/5325600
36.Kass, E.H. Pyelonephritis and bacteriuria. A major problem in preventive medicine. Ann Intern Med, 1962. 56: 46.
https://pubmed.ncbi.nlm.nih.gov/14454174
37.Kincaid-Smith, P., et al. Bacteriuria in Pregnancy. Lancet, 1965. 1: 395.
https://pubmed.ncbi.nlm.nih.gov/14238090
38.Little, P.J. The incidence of urinary infection in 5000 pregnant women. Lancet, 1966. 2: 925.
https://pubmed.ncbi.nlm.nih.gov/4162367
39.Mulla, N. Bacteriuria in pregnancy. Obstet Gynecol, 1960. 16: 89.
https://pubmed.ncbi.nlm.nih.gov/14425118
40.Pathak, U.N., et al. Bacteriuria of pregnancy: results of treatment. J Infect Dis, 1969. 120: 91.
https://pubmed.ncbi.nlm.nih.gov/5816817
41.Robertson, J.G., et al. The managment and complications of asymptomatic bacteriuria in pregnancy. Report of a study on 8,275 patients. J Obstet Gynaecol Br Commonw, 1968. 75: 59.
https://pubmed.ncbi.nlm.nih.gov/5635245
42.Thomsen, A.C., et al. Antibiotic elimination of group-B streptococci in urine in prevention of preterm labour. Lancet, 1987. 1: 591.
https://pubmed.ncbi.nlm.nih.gov/2881132
43.Williams, G.L., et al. Urinary concentrating ability in women with asymptomatic bacteriuria in pregnancy. Br Med J, 1969. 3: 212.
https://pubmed.ncbi.nlm.nih.gov/5792611
44.Wren, B.G. Subclinical renal infection and prematurity. Med J Aust, 1969. 2: 596.
https://pubmed.ncbi.nlm.nih.gov/5388374
45.Kazemier, B.M., et al. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis, 2015. 15: 1324.
https://pubmed.ncbi.nlm.nih.gov/26255208
46.Henderson, J.T., et al. Screening for Asymptomatic Bacteriuria in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 2019. 322: 1195.
https://pubmed.ncbi.nlm.nih.gov/31550037
47.Smaill, F.M., et al. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev, 2019. 2019: CD000490.
https://pubmed.ncbi.nlm.nih.gov/31765489
48.Wingert, A., et al. Asymptomatic bacteriuria in pregnancy: systematic reviews of screening and treatment effectiveness and patient preferences. BMJ Open, 2019. 9: e021347.
https://pubmed.ncbi.nlm.nih.gov/30872538
49.Christopher, L.J., et al. A trial of hippramine in the treatment of bacteriuria of pregnancy. Ir J Med Sci, 1969. 8: 331.
https://pubmed.ncbi.nlm.nih.gov/5806178
50.Reeves, D.S. Laboratory and clinical studies with sulfametopyrazine as a treatment for bacteriuria in pregnancy. J Antimicrob Chemother, 1975. 1: 171.
https://pubmed.ncbi.nlm.nih.gov/1100589
51.Whalley, P.J., et al. Short-term versus continuous antimicrobial therapy for asymptomatic bacteriuria in pregnancy. Obstet Gynecol, 1977. 49: 262.
https://pubmed.ncbi.nlm.nih.gov/320525
52.Bint, A., et al. A comparative trial of pivmecillinam and ampicillin in bacteriuria of pregnancy. Infection, 1979. 7: 290.
https://pubmed.ncbi.nlm.nih.gov/232697
53.Harris, R.E., et al. Single-dose antimicrobial therapy for asymptomatic bacteriuria during pregnancy. Obstet Gynecol, 1982. 59: 546.
https://pubmed.ncbi.nlm.nih.gov/7070725
54.Bailey, R.R., et al. Comparison of single dose with a 5-day course of co-trimoxazole for asymptomatic (covert) bacteriuria of pregnancy. Aust N Z J Obstet Gynaecol, 1983. 23: 139.
https://pubmed.ncbi.nlm.nih.gov/6606421
55.Masterton, R.G., et al. Single-dose amoxycillin in the treatment of bacteriuria in pregnancy and the puerperium--a controlled clinical trial. Br J Obstet Gynaecol, 1985. 92: 498.
https://pubmed.ncbi.nlm.nih.gov/3888250
56.Pedler, S.J., et al. Comparative study of amoxicillin-clavulanic acid and cephalexin in the treatment of bacteriuria during pregnancy. Antimicrob Agents Chemother, 1985. 27: 508.
https://pubmed.ncbi.nlm.nih.gov/4004191
57.Campbell-Brown, M., et al. Is screening for bacteriuria in pregnancy worth while? Br Med J (Clin Res Ed), 1987. 294: 1579.
https://pubmed.ncbi.nlm.nih.gov/3113538
58.Pregazzi, R., et al. [Single-dose antibiotic therapy of asymptomatic bacteriuria in pregnancy. Results and complications]. Minerva Ginecol, 1987. 39: 289.
https://pubmed.ncbi.nlm.nih.gov/3601207
59.Gerstner, G.J., et al. Amoxicillin in the treatment of asymptomatic bacteriuria in pregnancy: a single dose of 3 g amoxicillin versus a 4-day course of 3 doses 750 mg amoxicillin. Gynecol Obstet Invest, 1989. 27: 84.
https://pubmed.ncbi.nlm.nih.gov/2659442
60.Olsen, L., et al. Single-dose versus six-day therapy with sulfamethizole for asymptomatic bacteriuria during pregnancy. A prospective randomised study. Dan Med Bull, 1989. 36: 486.
https://pubmed.ncbi.nlm.nih.gov/2680315
61.Thoumsin, H., et al. Single dose fosfomycin trometamol versus multiple dose nitrofurantoin in pregnant women with bacteriuria: preliminary results. Infection, 1990. 18 Suppl 2: S94.
https://pubmed.ncbi.nlm.nih.gov/2286469
62.Bayrak, O., et al. Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimesterof pregnancy? Int Urogynecol J Pelvic Floor Dysfunct, 2007. 18: 525.
https://pubmed.ncbi.nlm.nih.gov/16941068
63.Estebanez, A., et al. Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. Eur J Clin Microbiol Infect Dis, 2009. 28: 1457.
https://pubmed.ncbi.nlm.nih.gov/19768649
64.Lumbiganon, P., et al. One-day compared with 7-day nitrofurantoin for asymptomatic bacteriuria in pregnancy: a randomized controlled trial. Obstet Gynecol, 2009. 113: 339.
https://pubmed.ncbi.nlm.nih.gov/19155904
65.Widmer, M., et al. Duration of treatment for asymptomatic bacteriuria during pregnancy. Cochrane Database Syst Rev, 2015. 2015: CD000491.
https://pubmed.ncbi.nlm.nih.gov/26560337
66.Wang, T., et al. Comparison of single-dose fosfomycin tromethamine and other antibiotics for lower uncomplicated urinary tract infection in women and asymptomatic bacteriuria in pregnant women: A systematic review and meta-analysis. Int J Antimicrob Agents, 2020. 56: 106018.
https://pubmed.ncbi.nlm.nih.gov/32417205
67.Zhanel, G.G., et al. Asymptomatic bacteriuria in patients with diabetes mellitus. Rev Infect Dis, 1991. 13: 150.
https://pubmed.ncbi.nlm.nih.gov/2017615
68.Harding, G.K., et al. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med, 2002. 347: 1576.
https://pubmed.ncbi.nlm.nih.gov/12432044
69.Mody, L., et al. Urinary tract infections in older women: a clinical review. JAMA, 2014. 311: 844.
https://pubmed.ncbi.nlm.nih.gov/24570248
70.Boscia, J.A., et al. Therapy vs no therapy for bacteriuria in elderly ambulatory nonhospitalized women. JAMA, 1987. 257: 1067.
https://pubmed.ncbi.nlm.nih.gov/3806896
71.Abrutyn, E., et al. Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women? Ann Intern Med, 1994. 120: 827.
https://pubmed.ncbi.nlm.nih.gov/7818631
72.Abrutyn, E., et al. Does treatment of asymptomatic bacteriuria in older ambulatory women reduce subsequent symptoms of urinary tract infection? J Am Geriatr Soc, 1996. 44: 293.
https://pubmed.ncbi.nlm.nih.gov/8600199
73.Nicolle, L.E., et al. Prospective randomized comparison of therapy and no therapy for asymptomatic bacteriuria in institutionalized elderly women. Am J Med, 1987. 83: 27.
https://pubmed.ncbi.nlm.nih.gov/3300325
74.Nicolle, L.E. Asymptomatic bacteriuria in the elderly. Infect Dis Clin North Am, 1997. 11: 647.
https://pubmed.ncbi.nlm.nih.gov/9378928
75.Silver, S.A., et al. Positive urine cultures: A major cause of inappropriate antimicrobial use in hospitals? Can J Infect Dis Med Microbiol, 2009. 20: 107.
https://pubmed.ncbi.nlm.nih.gov/21119801
76.Trautner, B.W. Asymptomatic bacteriuria: when the treatment is worse than the disease. Nat Rev Urol, 2011. 9: 85.
https://pubmed.ncbi.nlm.nih.gov/22143416
77.Nicolle, L.E., et al. Bacteriuria in elderly institutionalized men. N Engl J Med, 1983. 309: 1420.
https://pubmed.ncbi.nlm.nih.gov/6633618
78.Potts, L., et al. A double-blind comparative study of norfloxacin versus placebo in hospitalised elderly patients with asymptomatic bacteriuria. Arch Gerontol Geriatr, 1996. 23: 153.
https://pubmed.ncbi.nlm.nih.gov/15374159
79.Renneberg, J., et al. Single-day treatment with trimethoprim for asymptomatic bacteriuria in the elderly patient. J Urol, 1984. 132: 934.
https://pubmed.ncbi.nlm.nih.gov/6387184
80.Ouslander, J.G., et al. Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents? Ann Intern Med, 1995. 122: 749.
https://pubmed.ncbi.nlm.nih.gov/7717597
81.Krzyzaniak, N., et al. Antibiotics versus no treatment for asymptomatic bacteriuria in residents of aged care facilities: a systematic review and meta-analysis. Br J Gen Pract, 2022. 72: e649.
https://pubmed.ncbi.nlm.nih.gov/35940886
82.Moradi, M., et al. Effect of antibiotic therapy on asymptomatic bacteriuria in kidney transplant recipients. Urol J, 2005. 2: 32.
https://pubmed.ncbi.nlm.nih.gov/17629893
83.El Amari, E.B., et al. Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients. Nephrol Dial Transplant, 2011. 26: 4109.
https://pubmed.ncbi.nlm.nih.gov/21592976
84.Green, H., et al. Consequences of treated versus untreated asymptomatic bacteriuria in the first year following kidney transplantation: retrospective observational study. Eur J Clin Microbiol Infect Dis, 2013. 32: 127.
https://pubmed.ncbi.nlm.nih.gov/22918514
85.Origuen, J., et al. Should Asymptomatic Bacteriuria Be Systematically Treated in Kidney Transplant Recipients? Results From a Randomized Controlled Trial. Am J Transplant, 2016. 16: 2943.
https://pubmed.ncbi.nlm.nih.gov/27088545
86.Antonio, M.E.E., et al. Treatment of asymptomatic bacteriuria in the first 2 months after kidney transplant: A controlled clinical trial. Transpl Infect Dis, 2022. 24: e13934.
https://pubmed.ncbi.nlm.nih.gov/35980169
87.Sabe, N., et al. Antibiotic Treatment Versus No Treatment for Asymptomatic Bacteriuria in Kidney Transplant Recipients: A Multicenter Randomized Trial. Open Forum Infect Dis, 2019. 6: ofz243.
https://pubmed.ncbi.nlm.nih.gov/31214630
88.Arencibia, N., et al. Short-Term Outcome of Untreated Versus Treated Asymptomatic Bacteriuria in Renal Transplant Patients. Transplant Proc, 2016. 48: 2941.
https://pubmed.ncbi.nlm.nih.gov/27932112
89.Coussement, J., et al. Antibiotics for asymptomatic bacteriuria in kidney transplant recipients. Cochrane Database Syst Rev, 2018. 2: CD011357.
https://pubmed.ncbi.nlm.nih.gov/29390169
90.Gomez-Ochoa, S.A., et al. Systematic review and meta-analysis of asymptomatic bacteriuria after renal transplantation: incidence, risk of complications, and treatment outcomes. Transpl Infect Dis, 2020. 22: e13221.
https://pubmed.ncbi.nlm.nih.gov/31782870
91.Nicolle, L.E. Urinary tract infections in patients with spinal injuries. Curr Infect Dis Rep, 2014. 16: 390.
https://pubmed.ncbi.nlm.nih.gov/24445675
92.Wullt, B., et al. Bladder, bowel and bugs--bacteriuria in patients with intestinal urinary diversion. World J Urol, 2004. 22: 186.
https://pubmed.ncbi.nlm.nih.gov/15309491
93.Qu, L.G., et al. Systematic review: bacterial colonisation of conduits and neobladders-when to test, watch, and treat. World J Urol, 2020. 38: 1413.
https://pubmed.ncbi.nlm.nih.gov/31560122
94.Darouiche, R.O., et al. Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial. Clin Infect Dis, 2005. 41: 1531.
https://pubmed.ncbi.nlm.nih.gov/16231269
95.Sunden, F., et al. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol, 2010. 184: 179.
https://pubmed.ncbi.nlm.nih.gov/20483149
96.Bonkat, G., et al. Microbial biofilm formation and catheter-associated bacteriuria in patients with suprapubic catheterisation. World J Urol, 2013. 31: 565.
https://pubmed.ncbi.nlm.nih.gov/22926265
97.Tenke, P., et al. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents, 2008. 31 Suppl 1: S68.
https://pubmed.ncbi.nlm.nih.gov/18006279
98.Cooper, F.P., et al. Policies for replacing long-term indwelling urinary catheters in adults. Cochrane Database Syst Rev, 2016. 7: CD011115.
https://pubmed.ncbi.nlm.nih.gov/27457774
99.Dasgupta, R., et al. Preoperative antibiotics before endourologic surgery: current recommendations. J Endourol, 2009. 23: 1567.
https://pubmed.ncbi.nlm.nih.gov/19785548
100.Sobel, J.D., et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis, 2000. 30: 19.
https://pubmed.ncbi.nlm.nih.gov/10619727
101.Grabe, M., et al. The effect of a short antibiotic course in transurethral prostatic resection. Scand J Urol Nephrol, 1984. 18: 37.
https://pubmed.ncbi.nlm.nih.gov/6202000
102.Grabe, M., et al. Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery. Eur J Clin Microbiol, 1987. 6: 11.
https://pubmed.ncbi.nlm.nih.gov/3569248
103.Cafferkey, M.T., et al. Antibiotics for the prevention of septicaemia in urology. J Antimicrob Chemother, 1982. 9: 471.
https://pubmed.ncbi.nlm.nih.gov/7107549
104.Murphy, D.M., et al. Bacteraemia during prostatectomy and other transurethral operations: influence of timing of antibiotic administration. J Clin Pathol, 1984. 37: 673.
https://pubmed.ncbi.nlm.nih.gov/6725613
105.Chong, J.T., et al. Pre-procedural antibiotics for endoscopic urological procedures: Initial experience in individuals with spinal cord injury and asymptomatic bacteriuria. J Spinal Cord Med, 2015. 38: 187.
https://pubmed.ncbi.nlm.nih.gov/24621035
106.Cordero-Ampuero, J., et al. Are antibiotics necessary in hip arthroplasty with asymptomatic bacteriuria? Seeding risk with/without treatment. Clin Orthop Relat Res, 2013. 471: 3822.
https://pubmed.ncbi.nlm.nih.gov/23430723
107.Sousa, R., et al. Is asymptomatic bacteriuria a risk factor for prosthetic joint infection? Clin Infect Dis, 2014. 59: 41.
https://pubmed.ncbi.nlm.nih.gov/24723280
108.Rodriguez-Pardo, D., et al. Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial. Eur J Clin Microbiol Infect Dis, 2021. 40: 2411.
https://pubmed.ncbi.nlm.nih.gov/33864153
109.Gómez-Ochoa, S.A., et al. Risk of Surgical Site Infection in Patients with Asymptomatic Bacteriuria or Abnormal Urinalysis before Joint Arthroplasty: Systematic Review and Meta-Analysis. Surgical Infections, 2019. 20: 159.
https://pubmed.ncbi.nlm.nih.gov/30688601
110.Jami, S.A., et al. The necessity of treating asymptomatic bacteriuria with antibiotics in the perioperative period of joint arthroplasty: a metaanalysis. Turk J Med Sci, 2021. 51: 464.
https://pubmed.ncbi.nlm.nih.gov/33021755
111.Sousa, R.J.G., et al. Is Routine Urinary Screening Indicated Prior To Elective Total Joint Arthroplasty? A Systematic Review and Meta-Analysis. J Arthroplasty, 2019. 34: 1523.
https://pubmed.ncbi.nlm.nih.gov/30956050
112.Wang, C., et al. Current evidence does not support systematic antibiotherapy prior to joint arthroplasty in patients with asymptomatic bacteriuria-a meta analysis. Int Orthop, 2018. 42: 479.
https://pubmed.ncbi.nlm.nih.gov/29368046
113.Gomez-Ochoa, S.A., et al. Lack of Benefit on Treating Asymptomatic Bacteriuria Prior to Cardiovascular Surgery: a Systematic Review and Meta-Analysis. Braz J Cardiovasc Surg, 2018. 33: 641.
https://pubmed.ncbi.nlm.nih.gov/30652758
114.Foxman, B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon, 2003. 49: 53.
https://pubmed.ncbi.nlm.nih.gov/12601337
115.Wagenlehner, F.M., et al. Uncomplicated urinary tract infections. Dtsch Arztebl Int, 2011. 108: 415.
https://pubmed.ncbi.nlm.nih.gov/21776311
116.Stamm, W.E., et al. Management of urinary tract infections in adults. N Engl J Med, 1993. 329: 1328.
https://pubmed.ncbi.nlm.nih.gov/8413414
117.Foxman, B., et al. Urinary tract infection among women aged 40 to 65: behavioral and sexual risk factors. J Clin Epidemiol, 2001. 54: 710.
https://pubmed.ncbi.nlm.nih.gov/11438412
118.van Buul, L.W., et al. The Development of a Decision Tool for the Empiric Treatment of Suspected Urinary Tract Infection in Frail Older Adults: A Delphi Consensus Procedure. J Am Med Dir Assoc, 2018. 19: 757.
https://pubmed.ncbi.nlm.nih.gov/29910137
119.Bent, S., et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA, 2002. 287: 2701.
https://pubmed.ncbi.nlm.nih.gov/12020306
120.Bradbury, S.M. Collection of urine specimens in general practice: to clean or not to clean? J R Coll Gen Pract, 1988. 38: 363.
https://pubmed.ncbi.nlm.nih.gov/3256648
121.Lifshitz, E., et al. Outpatient urine culture: does collection technique matter? Arch Intern Med, 2000. 160: 2537.
https://pubmed.ncbi.nlm.nih.gov/10979067
122.Fihn, S.D. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med, 2003. 349: 259.
https://pubmed.ncbi.nlm.nih.gov/12867610
123.Foxman, B., et al. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am, 2003. 17: 227.
https://pubmed.ncbi.nlm.nih.gov/12848468
124.Falagas, M.E., et al. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. J Infect, 2009. 58: 91.
https://pubmed.ncbi.nlm.nih.gov/19195714
125.Gagyor, I., et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ, 2015. 351: h6544.
https://pubmed.ncbi.nlm.nih.gov/26698878
126.Vik, I., et al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial. PLoS Med, 2018. 15: e1002569.
https://pubmed.ncbi.nlm.nih.gov/29763434
127.Kronenberg, A., et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ, 2017. 359: j4784.
https://pubmed.ncbi.nlm.nih.gov/29113968
128.Wagenlehner, F.M., et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int, 2018. 101: 327.
https://pubmed.ncbi.nlm.nih.gov/30231252
129.Kaussner, Y., et al. Reducing antibiotic use in uncomplicated urinary tract infections in adult women: a systematic review and individual participant data meta-analysis. Clin Microbiol Infect, 2022. 28: 1558.
https://pubmed.ncbi.nlm.nih.gov/35788049
130.Gupta, K., et al. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med, 2007. 167: 2207.
https://pubmed.ncbi.nlm.nih.gov/17998493
131.Lecomte, F., et al. Single-dose treatment of cystitis with fosfomycin trometamol (Monuril): analysis of 15 comparative trials on 2,048 patients. . Giorn It Ost Gin, 1997. 19: 399.
https://www.sciencedirect.com/science/article/pii/S0399077X96802095
132.Nicolle, L.E. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother, 2000. 46 Suppl 1: 35.
https://pubmed.ncbi.nlm.nih.gov/11051622
133.Huttner, A., et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother, 2015. 70: 2456.
https://pubmed.ncbi.nlm.nih.gov/26066581
134.Gupta, K., et al. Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. Int J Antimicrob Agents, 2002. 19: 554.
https://pubmed.ncbi.nlm.nih.gov/12135847
135.Warren, J.W., et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis, 1999. 29: 745.
https://pubmed.ncbi.nlm.nih.gov/10589881
136.Hooton, T.M., et al. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA, 2012. 307: 583.
https://pubmed.ncbi.nlm.nih.gov/22318279
137.Hooton, T.M., et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA, 2005. 293: 949.
https://pubmed.ncbi.nlm.nih.gov/15728165
138.European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Quinolone and fluoroquinolone Article-31 referral, 2019.
139.Vazquez, J.C., et al. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database Syst Rev, 2000: CD002256.
https://pubmed.ncbi.nlm.nih.gov/10908537
140.Wagenlehner, F.M., et al. Antimicrobials in urogenital infections. Int J Antimicrob Agents, 2011. 38 Suppl: 3.
https://pubmed.ncbi.nlm.nih.gov/22019184
141.Geerts, A.F., et al. Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. Eur J Clin Pharmacol, 2013. 69: 1701.
https://pubmed.ncbi.nlm.nih.gov/23660771
142.Hooton, T.M. Recurrent urinary tract infection in women. Int J Antimicrob Agents, 2001. 17: 259.
https://pubmed.ncbi.nlm.nih.gov/11295405
143.Naber, K.G., et al. Psychosocial burden of recurrent uncomplicated urinary tract infections. GMS Infect Dis, 2022. 10: Doc01.
https://pubmed.ncbi.nlm.nih.gov/35463815
144.van Haarst, E.P., et al. Evaluation of the diagnostic workup in young women referred for recurrent lower urinary tract infections. Urology, 2001. 57: 1068.
https://pubmed.ncbi.nlm.nih.gov/11377307
145.Hooton, T.M., Prevention of recurrent urogenital tract infections in adult women, in EAU/International Consultation on Urological Infections. T, K.G. Naber, A.J. Schaeffer, C.F. Hynes & e. al., Editors. 2010, European Association of Urology: The Netherlands.
146.Cai, T., et al. Management of Recurrent Cystitis in Women: When Prompt Identification of Risk Factors Might Make a Difference. Eur Urol Focus, 2022. 8: 1476.
https://pubmed.ncbi.nlm.nih.gov/35135727
147.Adatto, K., et al. Behavioral factors and urinary tract infection. JAMA, 1979. 241: 2525.
https://pubmed.ncbi.nlm.nih.gov/439337
148.Lumsden, L., et al. Effects of an educational intervention on the rate of recurrent urinary tract infections in selected female outpatients. Women Health, 1985. 10: 79.
https://pubmed.ncbi.nlm.nih.gov/3984360
149.Hooton, T.M., et al. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Intern Med, 2018. 178: 1509.
https://pubmed.ncbi.nlm.nih.gov/30285042
150.Chen, Y.Y., et al. Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials. Int Urogynecol J, 2021. 32: 17.
https://pubmed.ncbi.nlm.nih.gov/32564121
151.Beerepoot, M.A., et al. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol, 2013. 190: 1981.
https://pubmed.ncbi.nlm.nih.gov/23867306
152.Leckie, K.J. What is the evidence for the role of oestrogen in the prevention of recurrent urinary tract infections in postmenopausal women? An evidence-based review. Journal of Clinical Gerontology and Geriatrics, 2010. 1: 31.
https://www.sciencedirect.com/science/article/pii/S2210833510000298?via%3Dihub
153.Duenas-Garcia, O.F., et al. Pharmacological Agents to Decrease New Episodes of Recurrent Lower Urinary Tract Infections in Postmenopausal Women. A Systematic Review. Female Pelvic Med Reconstr Surg, 2016. 22: 63.
https://pubmed.ncbi.nlm.nih.gov/26825411
154.Pinggera, G.M., et al. Effects of local estrogen therapy on recurrent urinary tract infections in young females under oral contraceptives. Eur Urol, 2005. 47: 243.
https://pubmed.ncbi.nlm.nih.gov/15661421
155.Aziminia, N., et al. Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int, 2019. 123: 753.
https://pubmed.ncbi.nlm.nih.gov/30378242
156.Prattley, S., et al. Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review. Eur Urol Focus, 2020. 6: 593.
https://pubmed.ncbi.nlm.nih.gov/31806578
157.Naber, K.G., et al. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents, 2009. 33: 111.
https://pubmed.ncbi.nlm.nih.gov/18963856
158.Nickel, J.C., et al. Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future. Can Urol Assoc J, 2020. 14: 281.
https://pubmed.ncbi.nlm.nih.gov/33626320
159.Lorenzo-Gómez, M.-F., et al. Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections. NEJM Evidence, 2022. 1: EVIDoa2100018.
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100018
160.Nestler, S., et al. Efficacy of vaccination with StroVac for recurrent urinary tract infections in women: a comparative single-centre study. Int Urol Nephrol, 2021. 53: 2267.
https://pubmed.ncbi.nlm.nih.gov/34499326
161.Kranz, J., et al. Current Evidence on Nonantibiotic Prevention of Recurrent Urinary Tract Infections. Eur Urol Focus, 2019. 5: 17.
https://pubmed.ncbi.nlm.nih.gov/30292420
162.Abad, C.L., et al. The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review. J Chemother, 2009. 21: 243.
https://pubmed.ncbi.nlm.nih.gov/19567343
163.Canales, J., et al. Are probiotics effective in preventing urinary tract infection? Medwave, 2018. 18: e7186.
https://pubmed.ncbi.nlm.nih.gov/29624569
164.Falagas, M.E., et al. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs, 2006. 66: 1253.
https://pubmed.ncbi.nlm.nih.gov/16827601
165.Grin, P.M., et al. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. Can J Urol, 2013. 20: 6607.
https://pubmed.ncbi.nlm.nih.gov/23433130
166.Hanson, L., et al. Probiotics for Treatment and Prevention of Urogenital Infections in Women: A Systematic Review. J Midwifery Womens Health, 2016. 61: 339.
https://pubmed.ncbi.nlm.nih.gov/27218592
167.Ng, Q.X., et al. Use of Lactobacillus spp. to prevent recurrent urinary tract infections in females. Med Hypotheses, 2018. 114: 49.
https://pubmed.ncbi.nlm.nih.gov/29602464
168.Akgul, T., et al. The role of probiotics in women with recurrent urinary tract infections. Turk J Urol, 2018. 44: 377.
https://pubmed.ncbi.nlm.nih.gov/30487041
169.Andreu, A. Lactobacillus as a probiotic for preventing urogenital infections. Reviews in Medical Microbiology, 2004. 15: 1.
170.Barrons, R., et al. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther, 2008. 30: 453.
https://pubmed.ncbi.nlm.nih.gov/18405785
171.Hoesl, C.E., et al. The probiotic approach: an alternative treatment option in urology. Eur Urol, 2005. 47: 288.
https://pubmed.ncbi.nlm.nih.gov/15716188
172.Ray, K. Infection: Lactobacillus probiotic could prevent recurrent UTI. Nat Rev Urol, 2011. 8: 292.
https://pubmed.ncbi.nlm.nih.gov/21660070
173.Reid, G., et al. Probiotics to prevent urinary tract infections: the rationale and evidence. World J Urol, 2006. 24: 28.
https://pubmed.ncbi.nlm.nih.gov/16389539
174.Abdullatif, V.A., et al. Efficacy of Probiotics as Prophylaxis for Urinary Tract Infections in Premenopausal Women: A Systematic Review and Meta-Analysis. Cureus, 2021. 13: e18843.
https://pubmed.ncbi.nlm.nih.gov/34671514
175.Jepson, R.G., et al. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev, 2012. 10: CD001321.
https://pubmed.ncbi.nlm.nih.gov/23076891
176.Fu, Z., et al. Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis. J Nutr, 2017. 147: 2282.
https://pubmed.ncbi.nlm.nih.gov/29046404
177.Luis, A., et al. Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections? A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Clinical Trials. J Urol, 2017. 198: 614.
https://pubmed.ncbi.nlm.nih.gov/28288837
178.Wang, C.H., et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med, 2012. 172: 988.
https://pubmed.ncbi.nlm.nih.gov/22777630
179.Tambunan, M.P., et al. Cranberries for women with recurrent urinary tract infection: a meta-analysis. Medical Journal of Indonesia, 2019. 28: 268.
http://mji.ui.ac.id/journal/index.php/mji/article/view/3299/1579
180.Xia, J.Y., et al. Consumption of cranberry as adjuvant therapy for urinary tract infections in susceptible populations: A systematic review and meta-analysis with trial sequential analysis. PLoS One, 2021. 16: e0256992.
https://pubmed.ncbi.nlm.nih.gov/34473789
181.Liska, D.J., et al. Cranberries and Urinary Tract Infections: How Can the Same Evidence Lead to Conflicting Advice? Adv Nutr, 2016. 7: 498.
https://pubmed.ncbi.nlm.nih.gov/27184277
182.Babar, A., et al. High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial. BMC Urol, 2021. 21: 44.
https://pubmed.ncbi.nlm.nih.gov/33757474
183.Lenger, S.M., et al. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol, 2020. 223: 265 e1.
https://pubmed.ncbi.nlm.nih.gov/32497610
184.Kyriakides, R., et al. Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature. Eur Urol Focus, 2021. 7: 1166.
https://pubmed.ncbi.nlm.nih.gov/32972899
185.Cooper, T.E., et al. D-mannose for preventing and treating urinary tract infections. Cochrane Database Syst Rev, 2022. 8: CD013608.
https://pubmed.ncbi.nlm.nih.gov/36041061
186.Damiano, R., et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol, 2011. 59: 645.
https://pubmed.ncbi.nlm.nih.gov/21272992
187.De Vita, D., et al. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J, 2012. 23: 1707.
https://pubmed.ncbi.nlm.nih.gov/22614285
188.Goddard, J.C., et al. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J, 2018. 29: 933.
https://pubmed.ncbi.nlm.nih.gov/29181550
189.Lee, B.S., et al. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev, 2012. 10: CD003265.
https://pubmed.ncbi.nlm.nih.gov/23076896
190.Bakhit, M., et al. Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis. Br J Gen Pract, 2021. 71: e528.
https://pubmed.ncbi.nlm.nih.gov/34001538
191.Harding, C., et al. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT. Health Technol Assess, 2022. 26: 1.
https://pubmed.ncbi.nlm.nih.gov/35535708
192.Harding, C., et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ, 2022. 376: e068229.
https://pubmed.ncbi.nlm.nih.gov/35264408
193.Nalliah, S., et al. The use of chemotherapeutic agents as prophylaxis for recurrent urinary tract infection in healthy nonpregnant women: A network meta-analysis. Indian J Urol, 2019. 35: 147.
https://pubmed.ncbi.nlm.nih.gov/31000921
194.Ahmed, H., et al. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials. BMJ Open, 2017. 7: e015233.
https://pubmed.ncbi.nlm.nih.gov/28554926
195.Price, J.R., et al. Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol, 2016. 215: 548.
https://pubmed.ncbi.nlm.nih.gov/27457111
196.Albert, X., et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev, 2004. 2004: CD001209.
https://pubmed.ncbi.nlm.nih.gov/15266443
197.Eells, S.J., et al. Recurrent urinary tract infections among women: comparative effectiveness of 5 prevention and management strategies using a Markov chain Monte Carlo model. Clin Infect Dis, 2014. 58: 147.
https://pubmed.ncbi.nlm.nih.gov/24065333
198.Anger, J., et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J Urol, 2019. 202: 282.
https://pubmed.ncbi.nlm.nih.gov/31042112
199.Kranz, J., et al. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int, 2018. 100: 271.
https://pubmed.ncbi.nlm.nih.gov/29539622
200.Epp, A., et al. No. 250-Recurrent Urinary Tract Infection. J Obstet Gynaecol Can, 2017. 39: e422.
https://pubmed.ncbi.nlm.nih.gov/28935065
201.Lichtenberger, P., et al. Antimicrobial prophylaxis in women with recurrent urinary tract infections. Int J Antimicrob Agents, 2011. 38 Suppl: 36.
https://pubmed.ncbi.nlm.nih.gov/22055655
202.Sen, A. Recurrent cystitis in non-pregnant women. BMJ Clin Evid, 2008. 2008.
https://pubmed.ncbi.nlm.nih.gov/19445741
203.Chew, L.D., et al. Recurrent cystitis in nonpregnant women. West J Med, 1999. 170: 274.
https://pubmed.ncbi.nlm.nih.gov/10379218
204.Rudenko, N., et al. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung, 2005. 55: 420.
https://pubmed.ncbi.nlm.nih.gov/16080282
205.Pfau, A., et al. Effective prophylaxis for recurrent urinary tract infections during pregnancy. Clin Infect Dis, 1992. 14: 810.
https://pubmed.ncbi.nlm.nih.gov/1576275
206.Schaeffer, A.J., et al. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. J Urol, 1999. 161: 207.
https://pubmed.ncbi.nlm.nih.gov/10037399
207.Scholes, D., et al. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med, 2005. 142: 20.
https://pubmed.ncbi.nlm.nih.gov/15630106
208.Hill, J.B., et al. Acute pyelonephritis in pregnancy. Obstet Gynecol, 2005. 105: 18.
https://pubmed.ncbi.nlm.nih.gov/15625136
209.Fulop, T. Acute Pyelonephritis Workup. 2012.
210.van Nieuwkoop, C., et al. Predicting the need for radiologic imaging in adults with febrile urinary tract infection. Clin Infect Dis, 2010. 51: 1266.
https://pubmed.ncbi.nlm.nih.gov/21034195
211.Cattrall, J.W.S., et al. A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis, 2018. 37: 2285.
https://pubmed.ncbi.nlm.nih.gov/30191339
212.Gupta, K., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis, 2011. 52: e103.
https://pubmed.ncbi.nlm.nih.gov/21292654
213.Berti, F., et al. Short versus long course antibiotic therapy for acute pyelonephritis in adults: a systematic review and meta-analysis. Italian Journal of Medicine, 2018. 12: 39.
https://www.italjmed.org/index.php/ijm/article/view/itjm.2018.840/1079
214.Hooton, T.M. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med, 2012. 366: 1028.
https://pubmed.ncbi.nlm.nih.gov/22417256
215.Arakawa, S., et al. The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection. J Infect Chemother, 2019. 25: 104.
https://pubmed.ncbi.nlm.nih.gov/30420153
216.Armstrong, E.S., et al. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections. BMC Infect Dis, 2016. 16: 710.
https://pubmed.ncbi.nlm.nih.gov/27887579
217.Huntington, J.A., et al. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother, 2016. 71: 2014.
https://pubmed.ncbi.nlm.nih.gov/26994090
218.Carmeli, Y., et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis, 2016. 16: 661.
https://pubmed.ncbi.nlm.nih.gov/27107460
219.Sims, M., et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother, 2017. 72: 2616.
https://pubmed.ncbi.nlm.nih.gov/28575389
220.Wagenlehner, F.M., et al. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis, 2016. 63: 754.
https://pubmed.ncbi.nlm.nih.gov/27313268
221.Kaye, K.S., et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA, 2018. 319: 788.
https://pubmed.ncbi.nlm.nih.gov/29486041
222.Wunderink, R.G., et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther, 2018. 7: 439.
https://pubmed.ncbi.nlm.nih.gov/30270406
223.Wagenlehner, F.M.E., et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med, 2019. 380: 729.
https://pubmed.ncbi.nlm.nih.gov/30786187
224.Portsmouth, S., et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis, 2018. 18: 1319.
https://pubmed.ncbi.nlm.nih.gov/30509675
225.Pitout, J.D. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs, 2010. 70: 313.
https://pubmed.ncbi.nlm.nih.gov/20166768
226.Mombelli, G., et al. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med, 1999. 159: 53.
https://pubmed.ncbi.nlm.nih.gov/9892331
227.Millar, L.K., et al. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial. Obstet Gynecol, 1995. 86: 560.
https://pubmed.ncbi.nlm.nih.gov/7675380
228.Wing, D.A., et al. A randomized trial of three antibiotic regimens for the treatment of pyelonephritis in pregnancy. Obstet Gynecol, 1998. 92: 249.
https://pubmed.ncbi.nlm.nih.gov/9699761
229.Ulleryd, P., et al. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis, 2003. 35: 34.
https://pubmed.ncbi.nlm.nih.gov/12685882
230.Reyner, K., et al. Urinary obstruction is an important complicating factor in patients with septic shock due to urinary infection. Am J Emerg Med, 2016. 34: 694.
https://pubmed.ncbi.nlm.nih.gov/26905806
231.Heyns, C.F. Urinary tract infection associated with conditions causing urinary tract obstruction and stasis, excluding urolithiasis and neuropathic bladder. World J Urol, 2012. 30: 77.
https://pubmed.ncbi.nlm.nih.gov/21720861
232.Spoorenberg, V., et al. [Better antibiotic use in complicated urinary tract infections; multicentre cluster randomised trial of 2 improvement strategies]. Ned Tijdschr Geneeskd, 2016. 160: D460.
https://pubmed.ncbi.nlm.nih.gov/27438395
233.Bader, M.S., et al. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med, 2017. 129: 242.
https://pubmed.ncbi.nlm.nih.gov/27712137
234.Geerlings, S.E., et al. SWAB Guidelines for Antimicrobial Therapy of Complicated Urinary Tract Infections in Adults. SWAB Guidelines, 2013.
https://swab.nl/exec/file/download/84
235.Hooton, T.M., et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis, 2010. 50: 625.
https://pubmed.ncbi.nlm.nih.gov/20175247
236.Peterson, J., et al. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006. Clin Ther, 2007. 29: 2215.
https://pubmed.ncbi.nlm.nih.gov/18042477
237.Bader, M.S., et al. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med, 2010. 122: 7.
https://pubmed.ncbi.nlm.nih.gov/21084776
238.Wagenlehner, F., et al. The Global Prevalence of Infections in Urology Study: A Long-Term, Worldwide Surveillance Study on Urological Infections. Pathogens, 2016. 5.
https://pubmed.ncbi.nlm.nih.gov/26797640
239.Popejoy, M.W., et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother, 2017. 72: 268.
https://pubmed.ncbi.nlm.nih.gov/27707990
240.Sternbach, N., et al. Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis. J Antimicrob Chemother, 2018. 73: 2021.
https://pubmed.ncbi.nlm.nih.gov/29659836
241.van der Starre, W.E., et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother, 2011. 66: 650.
https://pubmed.ncbi.nlm.nih.gov/21123286
242.Ren, H., et al. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial. Int Urol Nephrol, 2017. 49: 499.
https://pubmed.ncbi.nlm.nih.gov/28108978
243.Wagenlehner, F.M., et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet, 2015. 385: 1949.
https://pubmed.ncbi.nlm.nih.gov/25931244
244.Rudrabhatla, P., et al. Stopping the effective non-fluoroquinolone antibiotics at day 7 vs continuing until day 14 in adults with acute pyelonephritis requiring hospitalization: A randomized non-inferiority trial. PLoS One, 2018. 13: e0197302.
https://pubmed.ncbi.nlm.nih.gov/29768465
245.Gould, C.V., et al. Guideline for prevention of catheter-associated urinary tract infections 2009. Infect Control Hosp Epidemiol, 2010. 31: 319.
https://pubmed.ncbi.nlm.nih.gov/20156062
246.Magill, S.S., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med, 2014. 370: 1198.
https://pubmed.ncbi.nlm.nih.gov/24670166
247.Garibaldi, R.A., et al. Factors predisposing to bacteriuria during indwelling urethral catheterization. N Engl J Med, 1974. 291: 215.
https://pubmed.ncbi.nlm.nih.gov/4834750
248.Kunin, C.M., et al. Prevention of catheter-induced urinary-tract infections by sterile closed drainage. N Engl J Med, 1966. 274: 1155.
https://pubmed.ncbi.nlm.nih.gov/5934951
249.Hartstein, A.I., et al. Nosocomial urinary tract infection: a prospective evaluation of 108 catheterized patients. Infect Control, 1981. 2: 380.
https://pubmed.ncbi.nlm.nih.gov/6795141
250.Warren, J.W., et al. Fever, bacteremia, and death as complications of bacteriuria in women with long-term urethral catheters. J Infect Dis, 1987. 155: 1151.
https://pubmed.ncbi.nlm.nih.gov/3572035
251.Classen, D.C., et al. Prevention of catheter-associated bacteriuria: clinical trial of methods to block three known pathways of infection. Am J Infect Control, 1991. 19: 136.
https://pubmed.ncbi.nlm.nih.gov/1863002
252.Saint, S., et al. Preventing catheter-related bacteriuria: should we? Can we? How? Arch Intern Med, 1999. 159: 800.
https://pubmed.ncbi.nlm.nih.gov/10219925
253.Maki, D.G., et al. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis, 2001. 7: 342.
https://pubmed.ncbi.nlm.nih.gov/11294737
254.Li, F., et al. Risk factors for catheter-associated urinary tract infection among hospitalized patients: A systematic review and meta-analysis of observational studies. J Adv Nurs, 2019. 75: 517.
https://pubmed.ncbi.nlm.nih.gov/30259542
255.Jacobsen, S.M., et al. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev, 2008. 21: 26.
https://pubmed.ncbi.nlm.nih.gov/18202436
256.Durant, D.J. Nurse-driven protocols and the prevention of catheter-associated urinary tract infections: A systematic review. Am J Infect Control, 2017. 45: 1331.
https://pubmed.ncbi.nlm.nih.gov/28982611
257.Mody, L., et al. A targeted infection prevention intervention in nursing home residents with indwelling devices: a randomized clinical trial. JAMA Intern Med, 2015. 175: 714.
https://pubmed.ncbi.nlm.nih.gov/25775048
258.Meddings, J., et al. Systematic Review of Interventions to Reduce Urinary Tract Infection in Nursing Home Residents. J Hosp Med, 2017. 12: 356.
https://pubmed.ncbi.nlm.nih.gov/28459908
259.Kachare, S.D., et al. Toward eliminating catheter-associated urinary tract infections in an academic health center. J Surg Res, 2014. 192: 280.
https://pubmed.ncbi.nlm.nih.gov/25150082
260.Cao, Y., et al. Comparison of the preventive effect of urethral cleaning versus disinfection for catheter-associated urinary tract infections in adults: A network meta-analysis. Int J Infect Dis, 2018. 76: 102.
https://pubmed.ncbi.nlm.nih.gov/30243912
261.Noto, M.J., et al. Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. JAMA, 2015. 313: 369.
https://pubmed.ncbi.nlm.nih.gov/25602496
262.Huang, H.P., et al. The efficacy of daily chlorhexidine bathing for preventing healthcare-associated infections in adult intensive care units. Korean J Intern Med, 2016. 31: 1159.
https://pubmed.ncbi.nlm.nih.gov/27048258
263.Li, M., et al. The effect of bladder catheterization on the incidence of urinary tract infection in laboring women with epidural analgesia: a meta-analysis of randomized controlled trials. Int Urogynecol J, 2019. 30: 1419.
https://pubmed.ncbi.nlm.nih.gov/30834958
264.Gibson, K.E., et al. Indwelling urethral versus suprapubic catheters in nursing home residents: determining the safest option for long-term use. J Hosp Infect, 2019. 102: 219.
https://pubmed.ncbi.nlm.nih.gov/30056015
265.Kidd, E.A., et al. Urethral (indwelling or intermittent) or suprapubic routes for short-term catheterisation in hospitalised adults. Cochrane Database Syst Rev, 2015. 2015: CD004203.
https://pubmed.ncbi.nlm.nih.gov/26661940
266.Jamison, J., et al. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database Syst Rev, 2013. 18: CD004375.
https://pubmed.ncbi.nlm.nih.gov/24249436
267.Kranz, J., et al. Catheter-Associated Urinary Tract Infections in Adult Patients. Dtsch Arztebl Int, 2020. 117: 83.
https://pubmed.ncbi.nlm.nih.gov/32102727
268.Rognoni, C., et al. Intermittent catheterisation with hydrophilic and non-hydrophilic urinary catheters: systematic literature review and meta-analyses. BMC Urol, 2017. 17: 4.
https://pubmed.ncbi.nlm.nih.gov/28073354
269.Tradewell, M., et al. Systematic review and practice policy statements on urinary tract infection prevention in adults with spina bifida. Transl Androl Urol, 2018. 7: S205.
https://pubmed.ncbi.nlm.nih.gov/29928619
270.Akcam, F.Z., et al. An investigation of the effectiveness against bacteriuria of silver-coated catheters in short-term urinary catheter applications: A randomized controlled study. J Infect Chemother, 2019. 25: 797.
https://pubmed.ncbi.nlm.nih.gov/31030965
271.Singh, R., et al. Randomized controlled trial of silver-alloy-impregnated suprapubic catheters versus standard suprapubic catheters in assessing urinary tract infection rates in urogynecology patients. Int Urogynecol J, 2019. 30: 779.
https://pubmed.ncbi.nlm.nih.gov/30145671
272.Lam, T.B., et al. Types of indwelling urethral catheters for short-term catheterisation in hospitalised adults. Cochrane Database Syst Rev, 2014. 2014: CD004013.
https://pubmed.ncbi.nlm.nih.gov/25248140
273.Menezes, F.G., et al. A randomized clinical trial comparing Nitrofurazone-coated and uncoated urinary catheters in kidney transplant recipients: Results from a pilot study. Transpl Infect Dis, 2019. 21: e13031.
https://pubmed.ncbi.nlm.nih.gov/30451342
274.Bonfill, X., et al. Efficacy and safety of urinary catheters with silver alloy coating in patients with spinal cord injury: a multicentric pragmatic randomized controlled trial. The ESCALE trial. Spine J, 2017. 17: 1650.
https://pubmed.ncbi.nlm.nih.gov/28578163
275.Lusardi, G., et al. Antibiotic prophylaxis for short-term catheter bladder drainage in adults. Cochrane Database Syst Rev, 2013. 2013: CD005428.
https://pubmed.ncbi.nlm.nih.gov/23824735
276.Pickard, R., et al. Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: the AnTIC RCT. Health Technol Assess, 2018. 22: 1.
https://pubmed.ncbi.nlm.nih.gov/29766842
277.Cek, M., et al. Healthcare-associated urinary tract infections in hospitalized urological patients--a global perspective: results from the GPIU studies 2003-2010. World J Urol, 2014. 32: 1587.
https://pubmed.ncbi.nlm.nih.gov/24452449
278.Darouiche, R.O., et al. Short versus long course of antibiotics for catheter-associated urinary tract infections in patients with spinal cord injury: a randomized controlled noninferiority trial. Arch Phys Med Rehabil, 2014. 95: 290.
https://pubmed.ncbi.nlm.nih.gov/24035770
279.Saint, S., et al. Preventing Catheter-Associated Urinary Tract Infections. N Engl J Med, 2016. 375: 1298.
https://pubmed.ncbi.nlm.nih.gov/27682041
280.Bone, R.C., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 1992. 101: 1644.
https://pubmed.ncbi.nlm.nih.gov/1303622
281.Levy, M.M., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med, 2003. 31: 1250.
https://pubmed.ncbi.nlm.nih.gov/12682500
282.Dellinger, R.P., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med, 2013. 39: 165.
https://pubmed.ncbi.nlm.nih.gov/23361625
283.Martin, G.S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 2003. 348: 1546.
https://pubmed.ncbi.nlm.nih.gov/12700374
284.Hotchkiss, R.S., et al. The pathophysiology and treatment of sepsis. N Engl J Med, 2003. 348: 138.
https://pubmed.ncbi.nlm.nih.gov/12519925
285.Rosser, C.J., et al. Urinary tract infections in the critically ill patient with a urinary catheter. Am J Surg, 1999. 177: 287.
https://pubmed.ncbi.nlm.nih.gov/10326844
286.Brun-Buisson, C., et al. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med, 2004. 30: 580.
https://pubmed.ncbi.nlm.nih.gov/14997295
287.Tandogdu, Z., et al. Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013. World J Urol, 2016. 34: 1193.
https://pubmed.ncbi.nlm.nih.gov/26658886
288.Wilson, M.L., et al. Principles and rocedures for blood cultures; Approved Guideline. Clinical and Laboratory Standards Institute, 2007.
https://clsi.org/media/1448/m47a_sample.pdf
289.Howell, M.D., et al. Management of Sepsis and Septic Shock. JAMA, 2017. 317: 847.
https://pubmed.ncbi.nlm.nih.gov/28114603
290.Brunkhorst, F.M., et al. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med, 2000. 26 Suppl 2: S148.
https://pubmed.ncbi.nlm.nih.gov/18470710
291.Angeletti, S., et al. Procalcitonin, MR-Proadrenomedullin, and Cytokines Measurement in Sepsis Diagnosis: Advantages from Test Combination. Dis Markers, 2015. 2015: 951532.
https://pubmed.ncbi.nlm.nih.gov/26635427
292.Harbarth, S., et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med, 2001. 164: 396.
https://pubmed.ncbi.nlm.nih.gov/11500339
293.Mikkelsen, M.E., et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med, 2009. 37: 1670.
https://pubmed.ncbi.nlm.nih.gov/19325467
294.Carlet, J., et al. Guideliness for prevention of nosocomial infections in intensive care unit. Arnette Ed Paris 1994: 41.
295.Riedl, C.R., et al. Bacterial colonization of ureteral stents. Eur Urol, 1999. 36: 53.
https://pubmed.ncbi.nlm.nih.gov/10364656
296.DeGroot-Kosolcharoen, J., et al. Evaluation of a urinary catheter with a preconnected closed drainage bag. Infect Control Hosp Epidemiol, 1988. 9: 72.
https://pubmed.ncbi.nlm.nih.gov/3343502
297.Rivers, E., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med, 2001. 345: 1368.
https://pubmed.ncbi.nlm.nih.gov/11794169
298.Mouncey, P.R., et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med, 2015. 372: 1301.
https://pubmed.ncbi.nlm.nih.gov/25776532
299.Investigators, A., et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med, 2014. 371: 1496.
https://pubmed.ncbi.nlm.nih.gov/25272316
300.Pro, C.I., et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med, 2014. 370: 1683.
https://pubmed.ncbi.nlm.nih.gov/24635773
301.Investigators, P., et al. Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis. N Engl J Med, 2017. 376: 2223.
https://pubmed.ncbi.nlm.nih.gov/28320242
302.Monnet, X., et al. Prediction of fluid responsiveness: an update. Ann Intensive Care, 2016. 6: 111.
https://pubmed.ncbi.nlm.nih.gov/27858374
303.Dellinger, R.P., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med, 2004. 32: 858.
https://pubmed.ncbi.nlm.nih.gov/15090974
304.Zhang, N., et al. Are Ureaplasma spp. a cause of nongonococcal urethritis? A systematic review and meta-analysis. PLoS One, 2014. 9: e113771.
https://pubmed.ncbi.nlm.nih.gov/25463970
305.Horner, P.J., et al. 2016 European guideline on the management of non-gonococcal urethritis. Int J STD AIDS, 2016. 27: 928.
https://pubmed.ncbi.nlm.nih.gov/27147267
306.Workowski, K.A., et al. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep, 2015. 64: 1.
https://pubmed.ncbi.nlm.nih.gov/26042815
307.Bartoletti, R., et al. Management of Urethritis: Is It Still the Time for Empirical Antibiotic Treatments? Eur Urol Focus, 2019. 5: 29.
https://pubmed.ncbi.nlm.nih.gov/30318465
308.Jensen, J.S., et al. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol, 2016. 30: 1650.
https://pubmed.ncbi.nlm.nih.gov/27505296
309.Miller, J.M., et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis, 2018. 67: e1.
https://pubmed.ncbi.nlm.nih.gov/29955859
310.Wagenlehner, F.M., et al. The Presentation, Diagnosis, and Treatment of Sexually Transmitted Infections. Dtsch Arztebl Int, 2016. 113: 11.
https://pubmed.ncbi.nlm.nih.gov/26931526
311.Sena, A.C., et al. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations. Expert Rev Anti Infect Ther, 2014. 12: 673.
https://pubmed.ncbi.nlm.nih.gov/24555561
312.Shigemura, K., et al. History and epidemiology of antibiotic susceptibilities of Neisseria gonorrhoeae. Curr Drug Targets, 2015. 16: 272.
https://pubmed.ncbi.nlm.nih.gov/25410409
313.Hathorn, E., et al. The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review. Syst Rev, 2014. 3: 104.
https://pubmed.ncbi.nlm.nih.gov/25239090
314.Lau, A., et al. The Efficacy of Azithromycin for the Treatment of Genital Mycoplasma genitalium: A Systematic Review and Meta-analysis. Clin Infect Dis, 2015. 61: 1389.
https://pubmed.ncbi.nlm.nih.gov/26240201
315.Manhart, L.E., et al. Efficacy of Antimicrobial Therapy for Mycoplasma genitalium Infections. Clin Infect Dis, 2015. 61 Suppl 8: S802.
https://pubmed.ncbi.nlm.nih.gov/26602619
316.Paez-Canro, C., et al. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database Syst Rev, 2019. 1: CD010871.
https://pubmed.ncbi.nlm.nih.gov/30682211
317.Atkinson, L.M., et al. ‘The waiting game’: are current chlamydia and gonorrhoea near-patient/point-of-care tests acceptable to service users and will they impact on treatment? Int J STD AIDS, 2016. 27: 650.
https://pubmed.ncbi.nlm.nih.gov/26092579
318.Harding-Esch, E.M., et al. Impact of deploying multiple point-of-care tests with a ‘sample first’ approach on a sexual health clinical care pathway. A service evaluation. Sex Transm Infect, 2017. 93: 424.
https://pubmed.ncbi.nlm.nih.gov/28159916
319.Mensforth, S., et al. Auditing the use and assessing the clinical utility of microscopy as a point-of-care test for Neisseria gonorrhoeae in a Sexual Health clinic. Int J STD AIDS, 2018. 29: 157.
https://pubmed.ncbi.nlm.nih.gov/28705094
320.Moi, H., et al. Microscopy of Stained Urethral Smear in Male Urethritis; Which Cutoff Should be Used? Sex Transm Dis, 2017. 44: 189.
https://pubmed.ncbi.nlm.nih.gov/28178118
321.Sarier, M., et al. Microscopy of Gram-stained urethral smear in the diagnosis of urethritis: Which threshold value should be selected? Andrologia, 2018. 50: e13143.
https://pubmed.ncbi.nlm.nih.gov/30238498
322.Falk, L., et al. Time to eradication of Mycoplasma genitalium after antibiotic treatment in men and women. J Antimicrob Chemother, 2015. 70: 3134.
https://pubmed.ncbi.nlm.nih.gov/26283670
323.Khosropour, C.M., et al. Efficacy of standard therapies against Ureaplasma species and persistence among men with non-gonococcal urethritis enrolled in a randomised controlled trial. Sex Transm Infect, 2015. 91: 308.
https://pubmed.ncbi.nlm.nih.gov/25616607
324.Kirkcaldy, R.D., et al. Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014. MMWR Surveill Summ, 2016. 65: 1.
https://pubmed.ncbi.nlm.nih.gov/27414503
325.Ong, J.J., et al. Should Female Partners of Men With Non-Gonococcal Urethritis, Negative for Chlamydia trachomatis and Mycoplasma genitalium, Be Informed and Treated? Clinical Outcomes From a Partner Study of Heterosexual Men With NGU. Sex Transm Dis, 2017. 44: 126.
https://pubmed.ncbi.nlm.nih.gov/28079749
326.Read, T.R., et al. Azithromycin 1.5g Over 5 Days Compared to 1g Single Dose in Urethral Mycoplasma genitalium: Impact on Treatment Outcome and Resistance. Clin Infect Dis, 2017. 64: 250.
https://pubmed.ncbi.nlm.nih.gov/28011607
327.Read, T.R.H., et al. Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection. Emerg Infect Dis, 2018. 24: 328.
https://pubmed.ncbi.nlm.nih.gov/29350154
328.Salado-Rasmussen, K., et al. Mycoplasma genitalium testing pattern and macrolide resistance: a Danish nationwide retrospective survey. Clin Infect Dis, 2014. 59: 24.
https://pubmed.ncbi.nlm.nih.gov/24729494
329.Soda, M., et al. Evaluation of the Microbiological Efficacy of a Single 2-Gram Dose of Extended-Release Azithromycin by Population Pharmacokinetics and Simulation in Japanese Patients with Gonococcal Urethritis. Antimicrob Agents Chemother, 2018. 62: e01409.
https://pubmed.ncbi.nlm.nih.gov/29038284
330.Takahashi, S., et al. Clinical Efficacy of a Single Two Gram Dose of Azithromycin Extended Release for Male Patients with Urethritis. Antibiotics (Basel), 2014. 3: 109.
https://pubmed.ncbi.nlm.nih.gov/27025738
331.Unemo, M., et al. Five-day Azithromycin Treatment Regimen for Mycoplasma genitalium Infection Also Effectively Eradicates Chlamydia trachomatis. Acta Derm Venereol, 2015. 95: 730.
https://pubmed.ncbi.nlm.nih.gov/25823977
332.Yasuda, M., et al. A single 2 g oral dose of extended-release azithromycin for treatment of gonococcal urethritis. J Antimicrob Chemother, 2014. 69: 3116.
https://pubmed.ncbi.nlm.nih.gov/24948703
333.Yuan, Z., et al. Randomized controlled clinical trial on the efficacy of fosfomycin trometamol for uncomplicated gonococcal urethritis in men. Clin Microbiol Infect, 2016. 22: 507.
https://pubmed.ncbi.nlm.nih.gov/27064136
334.Berntsson, M., et al. Viral and bacterial aetiologies of male urethritis: findings of a high prevalence of Epstein-Barr virus. Int J STD AIDS, 2010. 21: 191.
https://pubmed.ncbi.nlm.nih.gov/20215624
335.Couldwell, D.L., et al. Ureaplasma urealyticum is significantly associated with non-gonococcal urethritis in heterosexual Sydney men. Int J STD AIDS, 2010. 21: 337.
https://pubmed.ncbi.nlm.nih.gov/20498103
336.Rietmeijer, C.A., et al. Recalibrating the Gram stain diagnosis of male urethritis in the era of nucleic acid amplification testing. Sex Transm Dis, 2012. 39: 18.
https://pubmed.ncbi.nlm.nih.gov/22183839
337.Centers for Disease, C., et al. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014. MMWR Recomm Rep, 2014. 63: 1.
https://pubmed.ncbi.nlm.nih.gov/24622331
338.Bissessor, M., et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis, 2015. 60: 1228.
https://pubmed.ncbi.nlm.nih.gov/25537875
339.Kirkcaldy, R.D., et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis, 2014. 59: 1083.
https://pubmed.ncbi.nlm.nih.gov/25031289
340.Kojima, M., et al. Single-dose treatment of male patients with gonococcal urethritis using 2g spectinomycin: microbiological and clinical evaluations. Int J Antimicrob Agents, 2008. 32: 50.
https://pubmed.ncbi.nlm.nih.gov/18539003
341.Lanjouw, E., et al. 2015 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS, 2016. 27: 333.
https://pubmed.ncbi.nlm.nih.gov/26608577
342.Lau, C.Y., et al. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis, 2002. 29: 497.
https://pubmed.ncbi.nlm.nih.gov/12218839
343.Moran, J.S., et al. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis, 1995. 20 Suppl 1: S47.
https://pubmed.ncbi.nlm.nih.gov/7795109
344.Unemo, M., et al. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev, 2014. 27: 587.
https://pubmed.ncbi.nlm.nih.gov/24982323
345.Muratani, T., et al. Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol, 2008. 15: 837.
https://pubmed.ncbi.nlm.nih.gov/18665871
346.Alexander, R.B., et al. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology, 1998. 52: 744.
https://pubmed.ncbi.nlm.nih.gov/9801092
347.Alexander, R.B., et al. Chronic prostatitis: results of an Internet survey. Urology, 1996. 48: 568.
https://pubmed.ncbi.nlm.nih.gov/8886062
348.Zermann, D.H., et al. Neurourological insights into the etiology of genitourinary pain in men. J Urol, 1999. 161: 903.
https://pubmed.ncbi.nlm.nih.gov/10022711
349.Perletti, G., et al. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev, 2013: CD009071.
https://pubmed.ncbi.nlm.nih.gov/23934982
350.Dadashpour. M, et al. Acute Prostatitis After Transrectal Ultrasound-guided Prostate Biopsy: Comparing Two Different Antibiotic Prophylaxis Regimen. Biomedical & Pharmacology Journal, 2016. 9: 593.
351.Schaeffer, A.J., et al. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol, 2005. 174: 161.
https://pubmed.ncbi.nlm.nih.gov/15947609
352.Skerk, V., et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents, 2003. 21: 457.
https://pubmed.ncbi.nlm.nih.gov/12727080
353.Vickovic, N., et al. Metronidazole 1.5 gram dose for 7 or 14 days in the treatment of patients with chronic prostatitis caused by Trichomonas vaginalis: A randomized study. J Chemother, 2010. 22: 364.
https://pubmed.ncbi.nlm.nih.gov/21123162
354.Cai, T., et al. Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. Int J Antimicrob Agents, 2009. 33: 549.
https://pubmed.ncbi.nlm.nih.gov/19181486
355.Aliaev Iu, G., et al. [Wardenafil in combined treatment of patients with chronic bacterial prostatitis]. Urologiia, 2008: 52.
https://pubmed.ncbi.nlm.nih.gov/19256057
356.Lipsky, B.A., et al. Treatment of bacterial prostatitis. Clin Infect Dis, 2010. 50: 1641.
https://pubmed.ncbi.nlm.nih.gov/20459324
357.Wise, G.J., et al. Atypical infections of the prostate. Current Prostate Reports, 2008. 6: 86.
https://link.springer.com/article/10.1007/s11918-008-0014-2
358.Turner, J.A., et al. Validity and responsiveness of the national institutes of health chronic prostatitis symptom index. J Urol, 2003. 169: 580.
https://pubmed.ncbi.nlm.nih.gov/12544311
359.Zegarra Montes, L.Z., et al. Semen and urine culture in the diagnosis of chronic bacterial prostatitis. Int Braz J Urol, 2008. 34: 30.
https://pubmed.ncbi.nlm.nih.gov/18341719
360.Budia, A., et al. Value of semen culture in the diagnosis of chronic bacterial prostatitis: a simplified method. Scand J Urol Nephrol, 2006. 40: 326.
https://pubmed.ncbi.nlm.nih.gov/16916775
361.Skerk, V., et al. The role of unusual pathogens in prostatitis syndrome. Int J Antimicrob Agents, 2004. 24 Suppl 1: S53.
https://pubmed.ncbi.nlm.nih.gov/15364308
362.Schneider, H., et al. The 2001 Giessen Cohort Study on patients with prostatitis syndrome--an evaluation of inflammatory status and search for microorganisms 10 years after a first analysis. Andrologia, 2003. 35: 258.
https://pubmed.ncbi.nlm.nih.gov/14535851
363.Naber, K.G., et al., Prostatitits, epididymitis and orchitis, in Infectious diseases, D. Armstrong & J. Cohen, Editors. 1999, Mosby: London.
364.Badalyan, R.R., et al. Chlamydial and ureaplasmal infections in patients with nonbacterial chronic prostatitis. Andrologia, 2003. 35: 263.
https://pubmed.ncbi.nlm.nih.gov/14535852
365.Berger, R.E., Epididymitis., in Sexually transmitted diseases, K.K. Holmes, P.-A. Mardh, P.F. Sparling & P.J. Wiesner, Editors. 1984, McGraw-Hill: New York.
366.Robinson, A.J., et al. Acute epididymitis: why patient and consort must be investigated. Br J Urol, 1990. 66: 642.
https://pubmed.ncbi.nlm.nih.gov/2265337
367.Schaeffer, A.J. Prostatitis: US perspective. Int J Antimicrob Agents, 1999. 11: 205.
https://pubmed.ncbi.nlm.nih.gov/10394972
368.Krieger, J.N., et al. NIH consensus definition and classification of prostatitis. JAMA, 1999. 282: 236.
https://pubmed.ncbi.nlm.nih.gov/10422990
369.(NIDDK), W.C.o.t.N.I.o.D.a.D.a.K.D., Chronic prostatitis workshop. 1995: Bethesda, Maryland.
370.Krieger, J.N., et al. Chronic pelvic pains represent the most prominent urogenital symptoms of “chronic prostatitis”. Urology, 1996. 48: 715.
https://pubmed.ncbi.nlm.nih.gov/8911515
371.Nickel, J.C. Effective office management of chronic prostatitis. Urol Clin North Am, 1998. 25: 677.
https://pubmed.ncbi.nlm.nih.gov/10026774
372.Etienne, M., et al. Performance of the urine leukocyte esterase and nitrite dipstick test for the diagnosis of acute prostatitis. Clin Infect Dis, 2008. 46: 951.
https://pubmed.ncbi.nlm.nih.gov/18288905
373.Meares, E.M., et al. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol, 1968. 5: 492.
https://pubmed.ncbi.nlm.nih.gov/4870505
374.Nickel, J.C., et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol, 2006. 176: 119.
https://pubmed.ncbi.nlm.nih.gov/16753385
375.Doble, A., et al. Ultrasonographic findings in prostatitis. Urol Clin North Am, 1989. 16: 763.
https://pubmed.ncbi.nlm.nih.gov/2683305
376.Papp, J.R., et al. Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae — 2014. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control, 2014. 63: 1.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047970/
377.Polascik, T.J., et al. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol, 1999. 162: 293.
https://pubmed.ncbi.nlm.nih.gov/10411025
378.Wagenlehner, F.M., et al. Bacterial prostatitis. World J Urol, 2013. 31: 711.
https://pubmed.ncbi.nlm.nih.gov/23519458
379.Gill, B.C., et al. Bacterial prostatitis. Curr Opin Infect Dis, 2016. 29: 86.
https://pubmed.ncbi.nlm.nih.gov/26555038
380.Wagenlehner, F.M., et al. Prostatitis: the role of antibiotic treatment. World J Urol, 2003. 21: 105.
https://pubmed.ncbi.nlm.nih.gov/12687400
381.Krieger, J.N. Recurrent lower urinary tract infections in men. J New Rem Clin, 1998. 47: 4.
382.Litwin, M.S., et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol, 1999. 162: 369.
https://pubmed.ncbi.nlm.nih.gov/10411041
383.Schaeffer, A.J., et al. Summary consensus statement: diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2003. 43: 1.
https://www.sciencedirect.com/science/article/abs/pii/S1569905602001914?via%3Dihub
384.Bjerklund Johansen, T.E., et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol, 1998. 34: 457.
https://pubmed.ncbi.nlm.nih.gov/9831786
385.Cai, T., et al. Clinical and microbiological efficacy of prulifloxacin for the treatment of chronic bacterial prostatitis due to Chlamydia trachomatis infection: results from a prospective, randomized and open-label study. Methods Find Exp Clin Pharmacol, 2010. 32: 39.
https://pubmed.ncbi.nlm.nih.gov/20383345
386.Smelov, V., et al. Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome. Andrologia, 2005. 37: 61.
https://pubmed.ncbi.nlm.nih.gov/16026425
387.Ohkawa, M., et al. Antimicrobial treatment for chronic prostatitis as a means of defining the role of Ureaplasma urealyticum. Urol Int, 1993. 51: 129.
https://pubmed.ncbi.nlm.nih.gov/8249222
388.Jimenez-Cruz, J.F., et al. Treatment of chronic prostatitis: intraprostatic antibiotic injections under echography control. J Urol, 1988. 139: 967.
https://pubmed.ncbi.nlm.nih.gov/3283385
389.Mayersak, J.S. Transrectal ultrasonography directed intraprostatic injection of gentamycin-xylocaine in the management of the benign painful prostate syndrome. A report of a 5 year clinical study of 75 patients. Int Surg, 1998. 83: 347.
https://pubmed.ncbi.nlm.nih.gov/10096759
390.Hua, L.X., et al. [The diagnosis and treatment of acute prostatitis: report of 35 cases]. Zhonghua Nan Ke Xue, 2005. 11: 897.
https://pubmed.ncbi.nlm.nih.gov/16398358
391.Yoon, B.I., et al. Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother, 2012. 18: 444.
https://pubmed.ncbi.nlm.nih.gov/22215226
392.Ludwig, M., et al. Diagnosis and therapeutic management of 18 patients with prostatic abscess. Urology, 1999. 53: 340.
https://pubmed.ncbi.nlm.nih.gov/9933051
393.Chou, Y.H., et al. Prostatic abscess: transrectal color Doppler ultrasonic diagnosis and minimally invasive therapeutic management. Ultrasound Med Biol, 2004. 30: 719.
https://pubmed.ncbi.nlm.nih.gov/15219951
394.Çek, M., et al. Acute and Chronic Epididymitis in EAU-EBU Update Series. Eur Urol Suppl 2017. 16: 124.
https://www.sciencedirect.com/science/article/abs/pii/S1569905617300568
395.Pilatz, A., et al. Acute epididymitis revisited: impact of molecular diagnostics on etiology and contemporary guideline recommendations. Eur Urol, 2015. 68: 428.
https://pubmed.ncbi.nlm.nih.gov/25542628
396.Harnisch, J.P., et al. Aetiology of acute epididymitis. Lancet, 1977. 1: 819.
https://pubmed.ncbi.nlm.nih.gov/67333
397.Shigemura, K., et al. Risk factors for febrile genito-urinary infection in the catheterized patients by with spinal cord injury-associated chronic neurogenic lower urinary tract dysfunction evaluated by urodynamic study and cystography: a retrospective study. World J Urol, 2020. 38: 733.
https://pubmed.ncbi.nlm.nih.gov/30949801
398.Street, E., et al. The 2016 European guideline on the management of epididymo-orchitis. IUSTI, 2016.
https://pubmed.ncbi.nlm.nih.gov/28632112
399.Chirwa, M., et al. United Kingdom British association for sexual health and HIV national guideline for the management of epididymo-orchitis, 2020. Int J STD AIDS, 2021. 32: 884.
https://pubmed.ncbi.nlm.nih.gov/34009058
400.Abbara, A., et al. Etiology and management of genitourinary tuberculosis. Nat Rev Urol, 2011. 8: 678.
https://pubmed.ncbi.nlm.nih.gov/22157940
401.Zitek, T., et al. Assessing the Utility of Ultrasound and Urinalysis for Patients with Possible Epididymo-Orchitis - A Retrospective Study. Open Access Emerg Med, 2020. 12: 47.
https://pubmed.ncbi.nlm.nih.gov/32214857
402.Capet, J., et al. Is follow-up ultrasound necessary after acute epididymitis? A retrospective analysis from a large university hospital. Scand J Urol, 2018. 52: 445.
https://pubmed.ncbi.nlm.nih.gov/30600755
403.Sadahira, T., et al. Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. J Infect Chemother, 2017. 23: 214.
https://pubmed.ncbi.nlm.nih.gov/28089362
404.Street, E., et al. BASHH 2010 United Kingdom national guideline for the management of epididymo-orchitis. 2010.
https://pubmed.ncbi.nlm.nih.gov/21729951
405.Fifer, H., et al. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae. Int J STD AIDS, 2020. 31: 4.
https://pubmed.ncbi.nlm.nih.gov/31870237
406.Eickhoff, J.H., et al. A double-blind, randomized, controlled multicentre study to compare the efficacy of ciprofloxacin with pivampicillin as oral therapy for epididymitis in men over 40 years of age. BJU Int, 1999. 84: 827.
https://pubmed.ncbi.nlm.nih.gov/10532980
407.Banyra, O., et al. Acute epididymo-orchitis: relevance of local classification and partner’s follow-up. Cent European J Urol, 2019. 72: 324.
https://pubmed.ncbi.nlm.nih.gov/31720038
408.Pilatz, A., et al. Impact of Bacterial Epididymitis on Semen Quality after Antibiotic Treatment. Journal of Urology, 2012. 187: e443.
https://university.auanet.org/abstract_detail.cfm?id=1092&meetingID=12ATL
409.Haddadeen, C., et al. Comparative regional audit of urology and genito-urinary departments in the management of acute epididymo-orchitis. HIV Medicine, 2010. 11: 45.
410.Nicholson, A., et al. Management of epididymo-orchitis in primary care: results from a large UK primary care database. Br J Gen Pract, 2010. 60: e407.
https://pubmed.ncbi.nlm.nih.gov/20883615
411.Andersen, B., et al. Impact of intensified testing for urogenital Chlamydia trachomatis infections: a randomised study with 9-year follow-up. Sex Transm Infect, 2011. 87: 156.
https://pubmed.ncbi.nlm.nih.gov/21097811
412.Chennamsetty, A., et al. Contemporary diagnosis and management of Fournier’s gangrene. Ther Adv Urol, 2015. 7: 203.
https://pubmed.ncbi.nlm.nih.gov/26445600
413.Eke, N. Fournier’s gangrene: a review of 1726 cases. Br J Surg, 2000. 87: 718.
https://pubmed.ncbi.nlm.nih.gov/10848848
414.Subrahmanyam, U., et al. Honey dressing beneficial in treatment of fournier’s gangrene. Indian J Surg, 2004. 66: 75.
https://tspace.library.utoronto.ca/retrieve/4733/IndianJournalofSurgery_2004_66_2_75_12453.pdf
415.Jallali, N., et al. Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. American Journal of Surgery, 2005. 189: 462.
https://pubmed.ncbi.nlm.nih.gov/15820462
416.Karian, L.S., et al. Reconstruction of Defects After Fournier Gangrene: A Systematic Review. Eplasty, 2015. 15: e18.
https://pubmed.ncbi.nlm.nih.gov/26171090
417.Furr, J., et al. Contemporary Trends in the Inpatient Management of Fournier’s Gangrene: Predictors of Length of Stay and Mortality Based on Population-based Sample. Urology, 2017. 102: 79.
https://pubmed.ncbi.nlm.nih.gov/27693572
418.Kim, S.Y., et al. A contemporary analysis of Fournier gangrene using the National Surgical Quality Improvement Program. Urology, 2015. 85: 1052.
https://pubmed.ncbi.nlm.nih.gov/25770725
419.Sorensen, M.D., et al. Fournier’s Gangrene: Epidemiology and Outcomes in the General US Population. Urol Int, 2016. 97: 249.
https://pubmed.ncbi.nlm.nih.gov/27172977
420.Roghmann, F., et al. Is there a need for the Fournier’s gangrene severity index? Comparison of scoring systems for outcome prediction in patients with Fournier’s gangrene. BJU International, 2012. 110: 1359.
https://pubmed.ncbi.nlm.nih.gov/22494217
421.Lauerman, M.H., et al. Less is more? Antibiotic duration and outcomes in Fournier’s gangrene. J Trauma Acute Care Surg, 2017. 83: 443.
https://pubmed.ncbi.nlm.nih.gov/28538648
422.Li, C., et al. Hyperbaric oxygen therapy as an adjuvant therapy for comprehensive treatment of Fournier’s gangrene. Urologia Internationalis, 2015. 94: 453.
https://pubmed.ncbi.nlm.nih.gov/25677386
423.Stevens, D.L., et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis, 2014. 59: 147.
https://pubmed.ncbi.nlm.nih.gov/24947530
424.Lyu, Z., et al. Human papillomavirus in semen and the risk for male infertility: a systematic review and meta-analysis. BMC Infect Dis, 2017. 17: 714.
https://pubmed.ncbi.nlm.nih.gov/29121862
425.Rodriguez-Alvarez, M.I., et al. Prevalence and Risk Factors of Human Papillomavirus in Male Patients: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health, 2018. 15: 2210.
https://pubmed.ncbi.nlm.nih.gov/30309014
426.Vaccarella, S., et al. Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study. J Infect Dis, 2011. 204: 1500.
https://pubmed.ncbi.nlm.nih.gov/21908729
427.Nakashima, K., et al. Risk factors for human papillomavirus detection in urine samples of heterosexual men visiting urological clinics in Japan. J Infect Chemother, 2018. 24: 713.
https://pubmed.ncbi.nlm.nih.gov/29759898
428.Luttmer, R., et al. Presence of human papillomavirus in semen in relation to semen quality. Hum Reprod, 2016. 31: 280.
https://pubmed.ncbi.nlm.nih.gov/26724799
429.Souho, T., et al. Human papillomavirus infection and fertility alteration: a systematic review. PLoS One, 2015. 10: e0126936.
https://pubmed.ncbi.nlm.nih.gov/25992782
430.Azevedo, J., et al. Epidemiology of human papillomavirus on anogenital warts in Portugal - The HERCOLES study. J Eur Acad Dermatol Venereol, 2017. 31: 1342.
https://pubmed.ncbi.nlm.nih.gov/28485812
431.Wei, F., et al. Sex Differences in the Incidence and Clearance of Anogenital Human Papillomavirus Infection in Liuzhou, China: An Observational Cohort Study. Clin Infect Dis, 2020. 70: 82.
https://pubmed.ncbi.nlm.nih.gov/30852604
432.Harder, T., et al. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Med, 2018. 16: 110.
https://pubmed.ncbi.nlm.nih.gov/30016957
433.Shigeishi, H., et al. Risk Factors for Oral Human Papillomavirus Infection in Healthy Individuals: A Systematic Review and Meta-Analysis. J Clin Med Res, 2016. 8: 721.
https://pubmed.ncbi.nlm.nih.gov/27635177
434.Tam, S., et al. The epidemiology of oral human papillomavirus infection in healthy populations: A systematic review and meta-analysis. Oral Oncol, 2018. 82: 91.
https://pubmed.ncbi.nlm.nih.gov/29909908
435.Dalla Torre, D., et al. The impact of sexual behavior on oral HPV infections in young unvaccinated adults. Clin Oral Investig, 2016. 20: 1551.
https://pubmed.ncbi.nlm.nih.gov/26526324
436.Geskus Rb, G.C.T.M.D.R.J.V.P.M.M.I.M.D.S.S.H.-N.B.O.M.D.A.J. Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: estimates and risk factors. AIDS (london, england), 2016. 30: 37.
https://pubmed.ncbi.nlm.nih.gov/26355673
437.Hebnes, J.B., et al. Prevalence of genital human papillomavirus among men in Europe: systematic review and meta-analysis. J Sex Med, 2014. 11: 2630.
https://pubmed.ncbi.nlm.nih.gov/25088239
438.Kaderli, R., et al. The impact of smoking on HPV infection and the development of anogenital warts. Int J Colorectal Dis, 2014. 29: 899.
https://pubmed.ncbi.nlm.nih.gov/24935346
439.Liu, M., et al. Transmission of genital human papillomavirus infection in couples: a population-based cohort study in rural China. Sci Rep, 2015. 5: 10986.
https://pubmed.ncbi.nlm.nih.gov/26204471
440.Taylor, S., et al. The incidence, clearance and persistence of non-cervical human papillomavirus infections: a systematic review of the literature. BMC Infect Dis, 2016. 16: 293.
https://pubmed.ncbi.nlm.nih.gov/27301867
441.Albero, G., et al. Male circumcision and prevalence of genital human papillomavirus infection in men: a multinational study. BMC Infect Dis, 2013. 13: 18.
https://pubmed.ncbi.nlm.nih.gov/23327450
442.Lam, J.U., et al. Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med Screen, 2014. 21: 38.
https://pubmed.ncbi.nlm.nih.gov/24488594
443.Larke, N., et al. Male circumcision and human papillomavirus infection in men: a systematic review and meta-analysis. J Infect Dis, 2011. 204: 1375.
https://pubmed.ncbi.nlm.nih.gov/21965090
444.Liu, Z., et al. Penises not required: a systematic review of the potential for human papillomavirus horizontal transmission that is non-sexual or does not include penile penetration. Sex Health, 2016. 13: 10.
https://pubmed.ncbi.nlm.nih.gov/26433493
445.Albero, G., et al. Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transm Dis, 2012. 39: 104.
https://pubmed.ncbi.nlm.nih.gov/22249298
446.Zaak, D., et al. Recurrence of condylomata acuminata of the urethra after conventional and fluorescence-controlled Nd:YAG laser treatment. Urology, 2003. 61: 1011.
https://pubmed.ncbi.nlm.nih.gov/12736026
447.Vives, A., et al. Urethral condylomas in men: experience in 123 patients without previous treatment. Int J STD AIDS, 2016. 27: 39.
https://pubmed.ncbi.nlm.nih.gov/25712107
448.Gilson, R., et al. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol, 2020. 34: 1644.
https://pubmed.ncbi.nlm.nih.gov/32735077
449.Edwards, L., et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol, 1998. 134: 25.
https://pubmed.ncbi.nlm.nih.gov/9449906
450.Saiag, P., et al. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. Br J Dermatol, 2009. 161: 904.
https://pubmed.ncbi.nlm.nih.gov/19466962
451.Grillo-Ardila, C.F., et al. Imiquimod for anogenital warts in non-immunocompromised adults. Cochrane Database Syst Rev, 2014: CD010389.
https://pubmed.ncbi.nlm.nih.gov/25362229
452.Tatti, S., et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol, 2008. 111: 1371.
https://pubmed.ncbi.nlm.nih.gov/18515521
453.Puviani, M., et al. Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO(2) ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial. Int J STD AIDS, 2019. 30: 131.
https://pubmed.ncbi.nlm.nih.gov/30236042
454.Werner, R.N., et al. Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis. Sex Transm Infect, 2017. 93: 155.
https://pubmed.ncbi.nlm.nih.gov/27803240
455.Camargo, C.L., et al. A prospective, open, comparative study of 5% potassium hydroxide solution versus cryotherapy in the treatment of genital warts in men. An Bras Dermatol, 2014. 89: 236.
https://pubmed.ncbi.nlm.nih.gov/24770498
456.Kodner, C.M., et al. Management of genital warts. Am Fam Physician, 2004. 70: 2335.
https://pubmed.ncbi.nlm.nih.gov/15617297
457.Scheinfeld, N., et al. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J, 2006. 12: 5.
https://pubmed.ncbi.nlm.nih.gov/16638419
458.Barton, S., et al. Effectiveness of topical and ablative therapies in treatment of anogenital warts: a systematic review and network meta-analysis. BMJ Open, 2019. 9: e027765.
https://pubmed.ncbi.nlm.nih.gov/31676644
459.Tobian, A.A., et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med, 2009. 360: 1298.
https://pubmed.ncbi.nlm.nih.gov/19321868
460.Schmeler, K.M., et al. Expanding the benefits of HPV vaccination to boys and men. Lancet, 2016. 387: 1798.
https://pubmed.ncbi.nlm.nih.gov/27203488
461.Rosales, R., et al. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther, 2014. 25: 1035.
https://pubmed.ncbi.nlm.nih.gov/25275724
462.Mikamo, H., et al. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study. Vaccine, 2019. 37: 1651.
https://pubmed.ncbi.nlm.nih.gov/30797638
463.Bergman, H., et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev, 2019. 2019: CD013479.
https://pubmed.ncbi.nlm.nih.gov/31755549
464.Dibble, K.E., et al. A Systematic Literature Review of HPV Vaccination Barriers Among Adolescent and Young Adult Males. J Adolesc Young Adult Oncol, 2019. 8: 495.
https://pubmed.ncbi.nlm.nih.gov/31090474
465.Richman Ar, T.E.G.E.J. A randomized intervention study to evaluate whether electronic messaging can increase HPV vaccine uptake and knowledge. Journal of lower genital tract disease, 2016. 20: S28.
https://journals.lww.com/jlgtd/Fulltext/2016/04001/2016_ASCCP_Poster_Presentation_Abstracts.2.aspx
466.European Center for Disease Pervention and Control/World Health Organisation. Tuberculosis surveillance and monitoring in Europe 2021 (2019 data). ECDC/WHO. ISBN 978-92-9498-534-7.
467.Hayward, S.E., et al. Extrapulmonary tuberculosis among migrants in Europe, 1995 to 2017. Clin Microbiol Infect, 2021. 27: 1347 e1.
https://pubmed.ncbi.nlm.nih.gov/33352301
468.Lawn, S.D., et al. Tuberculosis. Lancet, 2011. 378: 57.
https://pubmed.ncbi.nlm.nih.gov/21420161
469.Kang, W., et al. Epidemiology of concurrent extrapulmonary tuberculosis in inpatients with extrapulmonary tuberculosis lesions in China: a large-scale observational multi-centre investigation. Int J Infect Dis, 2022. 115: 79.
https://pubmed.ncbi.nlm.nih.gov/34781005
470.Vynnycky, E., et al. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect, 1997. 119: 183.
https://pubmed.ncbi.nlm.nih.gov/9363017
471.World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. ISBN 978-92-4-000150-3, 2020.
https://www.who.int/publications/i/item/9789240001503
472.Lewinsohn, D.M., et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis, 2017. 64: 111.
https://pubmed.ncbi.nlm.nih.gov/28052967
473.European Centre for Disease Prevention and Control. Mastering the basics of TB control: Development of a handbook on TB diagnostic methods. Stockholm, ECDC, 2011. ISBN 978-92-9193-242-9.
474.Ye, Y., et al. Clinical Features and Drug-Resistance Profile of Urinary Tuberculosis in South-Western China: A Cross-sectional Study. Medicine (Baltimore), 2016. 95: e3537.
https://pubmed.ncbi.nlm.nih.gov/27175652
475.Pingle, P., et al. Evaluation of Microscopy, Culture and PCR Methods in the Laboratory Diagnosis of Genito-urinary Tuberculosis. American Journal of Infectious Diseases and Microbiology, 2014. 2: 17.
http://pubs.sciepub.com/ajidm/2/1/4
476.Sun, L., et al. Rapid diagnosis in early stage renal tuberculosis by real-time polymerase chain reaction on renal biopsy specimens. Int J Tuberc Lung Dis, 2010. 14: 341.
https://pubmed.ncbi.nlm.nih.gov/20132626
477.Kumar, P., et al. Diagnosis of renal tuberculosis by real-time polymerase chain reaction in renal biopsy sample. World Journal of Pharmaceutical and Medical Research, 2017. 3: 285.
https://www.wjpmr.com/home/article_abstract/709
478.World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection 2021 update. ISBN 978-92-4-002941-5 https://www.who.int/publications/i/item/9789240029415
479.World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection. Web Annex 4. Evidence synthesis and analysis. ISBN 978-92-4-001026-0.
https://apps.who.int/iris/handle/10665/334150
480.Hemal, A.K., et al. Polymerase chain reaction in clinically suspected genitourinary tuberculosis: comparison with intravenous urography, bladder biopsy, and urine acid fast bacilli culture. Urology, 2000. 56: 570.
https://pubmed.ncbi.nlm.nih.gov/11018606
481.Muttarak, M., et al. Tuberculous epididymitis and epididymo-orchitis: sonographic appearances. AJR Am J Roentgenol, 2001. 176: 1459.
https://pubmed.ncbi.nlm.nih.gov/11373214
482.Yang, D.M., et al. Differential diagnosis of focal epididymal lesions with gray scale sonographic, color Doppler sonographic, and clinical features. J Ultrasound Med, 2003. 22: 135.
https://pubmed.ncbi.nlm.nih.gov/12562118
483.Li, S., et al. A better understanding of testicular and/or epididymal tuberculosis based on clinical, ultrasonic, computed tomography, and magnetic resonance imaging features at a high-volume institute in the modern era. Quant Imaging Med Surg, 2021. 11: 2465.
https://pubmed.ncbi.nlm.nih.gov/34079716
484.Jing, J., et al. Vas deferens sonographic appearances of tuberculosis lesions of 19 cases of male genital systemic tuberculosis. Medicine (Baltimore), 2019. 98: e14843.
https://pubmed.ncbi.nlm.nih.gov/30882677
485.Yang, D.M., et al. Chronic tuberculous epididymitis: color Doppler US findings with histopathologic correlation. Abdom Imaging, 2000. 25: 559.
https://pubmed.ncbi.nlm.nih.gov/10931999
486.Rui, X., et al. Ultrasonographic diagnosis and typing of renal tuberculosis. Int J Urol, 2008. 15: 135.
https://pubmed.ncbi.nlm.nih.gov/18269447
487.Radwan, A., et al. Multimodality Imaging of Genitourinary Tuberculosis. Curr Probl Diagn Radiol, 2021. 50: 867.
https://pubmed.ncbi.nlm.nih.gov/33272721
488.Baumgarten, D.A., et al. Imaging and radiologic management of upper urinary tract infections. Urol Clin North Am, 1997. 24: 545.
https://pubmed.ncbi.nlm.nih.gov/9275978
489.Muttarak, M., et al. Tuberculosis of the genitourinary tract: imaging features with pathological correlation. Singapore Med J, 2005. 46: 568.
https://pubmed.ncbi.nlm.nih.gov/16172781
490.Wang, Y., et al. Computerised tomography and intravenous pyelography in urinary tuberculosis: a retrospective descriptive study. Int J Tuberc Lung Dis, 2015. 19: 1441.
https://pubmed.ncbi.nlm.nih.gov/26614184
491.Sataa, S., et al. Imaging findings of urinary tuberculosis on computerized tomography versus excretory urography: Through 46 confirmed cases. Tunisie Medicale, 2014. 92: 743.
https://pubmed.ncbi.nlm.nih.gov/25879600
492.Wang, L.J., et al. Imaging findings of urinary tuberculosis on excretory urography and computerized tomography. J Urol, 2003. 169: 524.
https://pubmed.ncbi.nlm.nih.gov/12544301
493.Birnbaum, B.A., et al. Extrarenal genitourinary tuberculosis: CT appearance of calcified pipe-stem ureter and seminal vesicle abscess. J Comput Assist Tomogr, 1990. 14: 653.
https://pubmed.ncbi.nlm.nih.gov/2370364
494.Jung, Y.Y., et al. Genitourinary tuberculosis: comprehensive cross-sectional imaging. AJR Am J Roentgenol, 2005. 184: 143.
https://pubmed.ncbi.nlm.nih.gov/15615965
495.Wang, L.J., et al. CT features of genitourinary tuberculosis. J Comput Assist Tomogr, 1997. 21: 254.
https://pubmed.ncbi.nlm.nih.gov/9071295
496.Sharma, J.B., et al. Female genital tuberculosis: Revisited. Indian J Med Res, 2018. 148: S71.
https://pubmed.ncbi.nlm.nih.gov/30964083
497.Mantica, G., et al. Genitourinary Tuberculosis: A Comprehensive Review of a Neglected Manifestation in Low-Endemic Countries. Antibiotics (Basel), 2021. 10.
https://pubmed.ncbi.nlm.nih.gov/34827337
498.da Rocha, E.L., et al. Abdominal tuberculosis: a radiological review with emphasis on computed tomography and magnetic resonance imaging findings. Radiol Bras, 2015. 48: 181.
https://pubmed.ncbi.nlm.nih.gov/26185345
499.Cheng, Y., et al. Multiparametric Magnetic Resonance Imaging Characteristics of Prostate Tuberculosis. Korean J Radiol, 2015. 16: 846.
https://pubmed.ncbi.nlm.nih.gov/26175584
500.Ahmadi, F., et al. Hysterosalpingographic Appearances of Female Genital Tract Tuberculosis: Part II: Uterus. Int J Fertil Steril, 2014. 8: 13.
https://pubmed.ncbi.nlm.nih.gov/24696765
501.Ahmadi, F., et al. Hysterosalpingographic appearances of female genital tract tuberculosis: part I. Fallopian tube. Int J Fertil Steril, 2014. 7: 245.
https://pubmed.ncbi.nlm.nih.gov/24520493
502.Netter, A., et al. [Tuberculous endo-uterine symphysis; an anatomo-clinical and radiologically characteristic syndrome]. Gynecol Obstet (Paris), 1955. 54: 19.
https://pubmed.ncbi.nlm.nih.gov/14391756
503.World Health Organization. WHO consolidated guidelines on tuberculosis Module 4: Treatment: Drug-susceptible tuberculosis treatment 2022. ISBN 978-92-4-004812-6.
https://www.who.int/publications/i/item/9789240048126
504.European Centre for Disease Pervention and Control. European Union Standards for Tuberculosis Care 2017 update. ISBN 978-92-9498-247-6.
505.Huang, Y., et al. Surgical management of tuberculous epididymo-orchitis: a retrospective study of 81 cases with long-term follow-up. BMC Infect Dis, 2021. 21: 1068.
https://pubmed.ncbi.nlm.nih.gov/34654377
506.Mittal, A., et al. Surgical Management of Genitourinary Tuberculosis: our Experience and review of literature. Pol Przegl Chir, 2020. 92: 1.
https://pubmed.ncbi.nlm.nih.gov/33408264
507.Figueiredo, A.A., et al. Epidemiology of urogenital tuberculosis worldwide. Int J Urol, 2008. 15: 827.
https://pubmed.ncbi.nlm.nih.gov/18637157
508.Mochalova, T.P., et al. Reconstructive surgery for treatment of urogenital tuberculosis: 30 years of observation. World J Surg, 1997. 21: 511.
https://pubmed.ncbi.nlm.nih.gov/9204739
509.Gupta, N.P., et al. Reconstructive surgery for the management of genitourinary tuberculosis: a single center experience. J Urol, 2006. 175: 2150.
https://pubmed.ncbi.nlm.nih.gov/16697825
510.Kumar, A., et al. Can kidneys be saved in patients with urinary tuberculosis? A study in the era of modern chemotherapy and surgical armamentarium. Int J Urol, 2019. 26: 551.
https://pubmed.ncbi.nlm.nih.gov/30803052
511.Pal, D.K., et al. Role of surgical intervention in genitourinary tuberculosis in the era of modern anti-tubercular chemotherapy. Sch. J. App. Med. Sci, 2015. 3: 1608.
https://journals.indexcopernicus.com/api/file/viewByFileId/362945.pdf
512.Li, X., et al. A Clinical Comparative Analysis of Retroperitoneal Laparoscopic Tuberculous Nephrectomy and Open Tuberculous Nephrectomy. J Laparoendosc Adv Surg Tech A, 2019. 29: 909.
https://pubmed.ncbi.nlm.nih.gov/30932738
513.Zhang, S., et al. Open surgery versus retroperitoneal laparoscopic nephrectomy for renal tuberculosis: a retrospective study of 120 patients. PeerJ, 2016. 4: e2708.
https://pubmed.ncbi.nlm.nih.gov/27917313
514.Kim, H.H., et al. Laparoscopic nephrectomy for nonfunctioning tuberculous kidney. J Endourol, 2000. 14: 433.
https://pubmed.ncbi.nlm.nih.gov/10958566
515.Han, W.K., et al. The feasibility of laparoendoscopic single-site nephrectomy: initial experience using home-made single-port device. Urology, 2010. 76: 862.
https://pubmed.ncbi.nlm.nih.gov/20110116
516.Hemal, A.K., et al. Comparison of retroperitoneoscopic nephrectomy with open surgery for tuberculous nonfunctioning kidneys. J Urol, 2000. 164: 32.
https://pubmed.ncbi.nlm.nih.gov/10840418
517.European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 – Healthcare-associated infections acquired in intensive care units. 2016.
518.Control, C.f.D. Procedure-associated Module 9: Surgical Site Infection (SSI) Event. . 2017.
https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf
519.Tanner, J., et al. Surgical hand antisepsis to reduce surgical site infection. Cochrane Database Syst Rev, 2016. 2016: CD004288.
https://pubmed.ncbi.nlm.nih.gov/26799160
520.Webster, J., et al. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev, 2015. 2015: CD004985.
https://pubmed.ncbi.nlm.nih.gov/25927093
521.Tanner, J., et al. Preoperative hair removal to reduce surgical site infection. Cochrane Database Syst Rev, 2011: CD004122.
https://pubmed.ncbi.nlm.nih.gov/22071812
522.Arnold, A., et al. Preoperative Mechanical Bowel Preparation for Abdominal, Laparoscopic, and Vaginal Surgery: A Systematic Review. J Minim Invasive Gynecol, 2015. 22: 737.
https://pubmed.ncbi.nlm.nih.gov/25881881
523.Guenaga, K.F., et al. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev, 2011. 2011: CD001544.
https://pubmed.ncbi.nlm.nih.gov/21901677
524.Dumville, J.C., et al. Preoperative skin antiseptics for preventing surgical wound infections after clean surgery. Cochrane Database Syst Rev, 2015. 2015: CD003949.
https://pubmed.ncbi.nlm.nih.gov/25897764
525.Webster, J., et al. Use of plastic adhesive drapes during surgery for preventing surgical site infection. Cochrane Database Syst Rev, 2015. 2015: CD006353.
https://pubmed.ncbi.nlm.nih.gov/25901509
526.Bonkat, G., et al. Non-molecular Methods to Detect Bacteriuria Prior to Urological Interventions: A Diagnostic Accuracy Systematic Review. Eur Urol Focus, 2017. 3: 535.
https://pubmed.ncbi.nlm.nih.gov/29627196
527.Control., E.C.f.D.P.a. Systematic review and evidence-based guidance on perioperative antibiotic prophylaxis. 2013.
528.Anonymous. Antibacterial prophylaxis in surgery: 2 - Urogenital, obstetric and gynaecological surgery. Drug and Therapeutics Bulletin, 2004. 42: 9.
https://pubmed.ncbi.nlm.nih.gov/15067952
529.Benseler, A., et al. Antibiotic prophylaxis for urodynamic testing in women: a systematic review. Int Urogynecol J, 2021. 32: 27.
https://pubmed.ncbi.nlm.nih.gov/32845398
530.Foon, R., et al. Prophylactic antibiotics to reduce the risk of urinary tract infections after urodynamic studies [Systematic Review]. Cochrane Database of Systematic Reviews, 2012. 10: 10.
https://pubmed.ncbi.nlm.nih.gov/23076941
531.Carey, M.M., et al. Should We Use Antibiotic Prophylaxis for Flexible Cystoscopy? A Systematic Review and Meta-Analysis. Urol Int, 2015. 95: 249.
https://pubmed.ncbi.nlm.nih.gov/26138144
532.Garcia-Perdomo, H.A., et al. Efficacy of antibiotic prophylaxis in cystoscopy to prevent urinary tract infection: a systematic review and meta-analysis. Int Braz J Urol, 2015. 41: 412.
https://pubmed.ncbi.nlm.nih.gov/26200530
533.Zeng, S., et al. Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy. Cochrane Database Syst Rev, 2019. 2: CD012305.
https://pubmed.ncbi.nlm.nih.gov/30789676
534.Bradshaw, A.W., et al. Antibiotics are not necessary during routine cystoscopic stent removal: A randomized controlled trial at UC San Diego. Urol Ann, 2020. 12: 373.
https://pubmed.ncbi.nlm.nih.gov/33776335
535.Lu, Y., et al. Antibiotic prophylaxis for shock wave lithotripsy in patients with sterile urine before treatment may be unnecessary: a systematic review and meta-analysis. J Urol, 2012. 188: 441.
https://pubmed.ncbi.nlm.nih.gov/22704118
536.Mrkobrada, M., et al. CUA Guidelines on antibiotic prophylaxis for urologic procedures. Can Urol Assoc J, 2015. 9: 13.
https://pubmed.ncbi.nlm.nih.gov/25737749
537.Hsieh, C.H., et al. The Effectiveness of Prophylactic Antibiotics with Oral Levofloxacin against Post-Shock Wave Lithotripsy Infectious Complications: A Randomized Controlled Trial. Surg Infect (Larchmt), 2016. 17: 346.
https://pubmed.ncbi.nlm.nih.gov/26910613
538.Shafi, H., et al. Antibiotic prophylaxis in the prevention of urinary tract infection in patients with sterile urine before extracorporeal shock wave lithotripsy. Caspian J Intern Med, 2018. 9: 296.
https://pubmed.ncbi.nlm.nih.gov/30197776
539.Lin, H.Y., et al. Atomoxetine Treatment Strengthens an Anti-Correlated Relationship between Functional Brain Networks in Medication-Naive Adults with Attention-Deficit Hyperactivity Disorder: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Int J Neuropsychopharmacol, 2015. 19: pyv094.
https://pubmed.ncbi.nlm.nih.gov/26377368
540.Deng, T., et al. Antibiotic prophylaxis in ureteroscopic lithotripsy: a systematic review and meta-analysis of comparative studies. BJU Int, 2018. 122: 29.
https://pubmed.ncbi.nlm.nih.gov/29232047
541.Zhao, Z., et al. Recommended antibiotic prophylaxis regimen in retrograde intrarenal surgery: evidence from a randomised controlled trial. BJU Int, 2019. 124: 496.
https://pubmed.ncbi.nlm.nih.gov/31136070
542.Qiao, L.D., et al. Evaluation of perioperative prophylaxis with fosfomycin tromethamine in ureteroscopic stone removal: an investigator-driven prospective, multicenter, randomized, controlled study. Int Urol Nephrol, 2018. 50: 427.
https://pubmed.ncbi.nlm.nih.gov/29290000
543.Yu, J., et al. Antibiotic prophylaxis in perioperative period of percutaneous nephrolithotomy: a systematic review and meta-analysis of comparative studies. World J Urol, 2020. 38: 1685.
https://pubmed.ncbi.nlm.nih.gov/31562533
544.Seyrek, M., et al. Perioperative prophylaxis for percutaneous nephrolithotomy: randomized study concerning the drug and dosage. J Endourol, 2012. 26: 1431.
https://pubmed.ncbi.nlm.nih.gov/22612061
545.Tuzel, E., et al. Prospective comparative study of two protocols of antibiotic prophylaxis in percutaneous nephrolithotomy. J Endourol, 2013. 27: 172.
https://pubmed.ncbi.nlm.nih.gov/22908891
546.Omar, M., et al. Ciprofloxacin infusion versus third generation cephalosporin as a surgical prophylaxis for percutaneous nephrolithotomy: a randomized study. Cent European J Urol, 2019. 72: 57.
https://pubmed.ncbi.nlm.nih.gov/31011442
547.Taken, K., et al. Comparison of Ceftriaxone and Cefazolin Sodium Antibiotic Prophylaxis in Terms of SIRS/Urosepsis Rates in Patients Undergoing Percutaneous Nephrolithotomy. J Urol Surg, 2019. 6: 111.
http://mji.ui.ac.id/journal/index.php/mji/article/view/3299/1579
548.Dahm, P., et al. Evidence-based Urology. BMJ Books London, 2010: 50.
549.Bausch, K., et al. Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-Analysis. J Urol, 2021. 205: 987.
https://pubmed.ncbi.nlm.nih.gov/33284673
550.Yang, J., et al. Prospective, randomized controlled study of the preventive effect of fosfomycin tromethamine on post-transurethral resection of bladder tumor urinary tract infection. Int J Urol, 2018. 25: 894.
https://pubmed.ncbi.nlm.nih.gov/29999216
551.Sanaee, M.S., et al. Urinary tract infection prevention after midurethral slings in pelvic floor reconstructive surgery: A systematic review and meta-analysis. Acta Obstet Gynecol Scand, 2019. 98: 1514.
https://pubmed.ncbi.nlm.nih.gov/31112286
552.Crawford, D., et al. Infectious Outcomes from Renal Tumor Ablation: Prophylactic Antibiotics or Not? Cardiovasc Intervent Radiol, 2018. 41: 1573.
https://pubmed.ncbi.nlm.nih.gov/30062444
553.Pradere, B., et al. Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. J Urol, 2021. 205: 653.
https://pubmed.ncbi.nlm.nih.gov/33026903
554.Lam, W., et al. Abstracts of the Hong Kong Urological Association 26th Annual Scientific Meeting, Hong Kong, 17 October 2021. BJU Int, 2022. 129 Suppl 1: 4.
https://pubmed.ncbi.nlm.nih.gov/35202507
555.Bennett, H.Y., et al. The global burden of major infectious complications following prostate biopsy. Epidemiol Infect, 2016. 144: 1784.
https://pubmed.ncbi.nlm.nih.gov/26645476
556.Berry, B., et al. Comparison of complications after transrectal and transperineal prostate biopsy: a national population-based study. BJU Int, 2020. 126: 97.
https://pubmed.ncbi.nlm.nih.gov/32124525
557.Castellani, D., et al. Infection Rate after Transperineal Prostate Biopsy with and without Prophylactic Antibiotics: Results from a Systematic Review and Meta-Analysis of Comparative Studies. J Urol, 2022. 207: 25.
https://pubmed.ncbi.nlm.nih.gov/34555932
558.Basourakos, S.P., et al. Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. Eur Urol Open Sci, 2022. 37: 53.
https://pubmed.ncbi.nlm.nih.gov/35243391
559.Chernysheva, D.Y., et al. The first experience of transperineal prostate biopsy without antibiotic prophylaxis. Cancer Urology, 2021. 17: 46.
https://oncourology.abvpress.ru/oncur/article/view/1392?locale=en_US
560.Jacewicz, M., et al. Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. Lancet Infect Dis, 2022. 22: 1465.
https://pubmed.ncbi.nlm.nih.gov/35839791
561.Shaker, H.S., et al. Does The Use Of Povidone Iodine Suppository Decrease The Infective Complications Of TRUS Guided Prostate Biopsies? A Randomized Prospective Study. QJM: An International Journal of Medicine, 2020. 113.
https://academic.oup.com/qjmed/article/113/Supplement_1/hcaa070.024/5829649?login=false
562.Ergani, B., et al. Effect of rectal mucosa cleansing on acute prostatitis during prostate biopsy: A randomized prospective study. Turk J Urol, 2020. 46: 159.
https://pubmed.ncbi.nlm.nih.gov/31922485
563.Farooq, K., et al. Role of Povidone-Iodine-Soaked Gauze in Preventing Infectious Complications Following Trans Rectal Digital Guided Prostate Biopsy. Journal of Postgraduate Medical Institute, 2021. 35: 225.
https://jpmi.org.pk/index.php/jpmi/article/view/2849
564.Taher, Y., et al. (2014) Prospective randomized controlled study to assess the effect of perineal region cleansing with povidone iodine before transrectal needle biopsy of the prostate on infectious complications. Urology 84, S306 DOI: http://dx.doi.org/10.1016/S0090-4295%2814%2901020-6.
565.Yu, L., et al. [Impact of insertion timing of iodophor cotton ball on the control of infection complications after transrectal ultrasound guided prostate biopsy]. Zhonghua Yi Xue Za Zhi, 2014. 94: 609.
https://pubmed.ncbi.nlm.nih.gov/24762693
566.Ezenwa, E.V., et al. Apical peri-prostatic nerve block versus intra-rectal xylocaine gel for trans- rectal ultrasound guided prostate biopsy among Nigerian patients: A prospective randomized study. Niger J Clin Pract, 2020. 23: 1183.
https://pubmed.ncbi.nlm.nih.gov/32913154
567.Jang, H., et al. Comparison of intrarectal heated lidocaine gel and periprostatic nerve block for pain control in transrectal ultrasound-guided prostate biopsy: A randomized controlled non-inferiority trial. Prostate Int, 2023. 11: 8.
https://pubmed.ncbi.nlm.nih.gov/36910899
568.Russo, F., et al. MR-TARGETED VS. TRUS-GUIDED PROSTATE BIOPSY IN PATIENTS WITH HIGH PSA VALUES: A RANDOMIZED CONTROLLED TRIAL. Anticancer Research, 2016. 36: 2556.
https://ar.iiarjournals.org/content/anticanres/36/5/2535.full.pdf
569.Pilatz, A., et al. Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. J Urol, 2020. 204: 224.
https://pubmed.ncbi.nlm.nih.gov/32105195
570.Supreeth, N., et al. Prospective randomized controlled study of comparing efficacy of prophylactic intraprostatic antibiotic injection with oral antibiotic verses standard oral prophylaxis in patients undergoing transrectal ultrasonography guided prostate biopsy. Indian Journal of Urology, 2023. 39: S3.
571.Andreasson, A., et al. Fosfomycin versus Ciprofloxacin as transrectal prostatebiopsy antibiotic prophylaxis – an open randomized controlled multicenter drug trial. European Urology, 2023. 83: S180.
https://www.sciencedirect.com/science/article/pii/S0302283823001835
572.Carignan, A., et al. Effectiveness of fosfomycin tromethamine prophylaxis in preventing infection following transrectal ultrasound-guided prostate needle biopsy: Results from a large Canadian cohort. J Glob Antimicrob Resist, 2019. 17: 112.
https://pubmed.ncbi.nlm.nih.gov/30553114
573.Pilatz, A., et al. European Association of Urology Position Paper on the Prevention of Infectious Complications Following Prostate Biopsy. Eur Urol, 2021. 79: 11.